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INTRODUCTION 
          Chronic illnesses are non-communicable illnesses that last for a very 
long time,   usually do not resolve spontaneously and rarely cured completely. 
These illnesses are the foremost causes of disability and death among the 
most treatable and preventable of all health related problems.  Chronic 
diseases include illness such as heart diseases, diabetes mellitus, systemic 
hypertension, cancer , chronic obstructive lung disease, epilepsy and arthritis. 
         Mental health illnesses are medical conditions that disrupt a person's   
emotions, thinking, behavior,   mood, self  care, interpersonal relationship and 
daily functioning. They are medical   conditions that often result in a reduced 
capability to cope with the routine daily activities.   
         The relationship between mental health illnesses and   chronic physical 
conditions are significant.  Regardless of etiology, chronic illnesses and 
mental health illnesses are treatable and both the conditions are common and 
disabling among general population. Individuals with chronic medical 
illnesses have increased risk for mental illnesses such as depression and 
anxiety as compared to the physically healthy people. Mental health care 
priorities need to be focused  attention from psychotic disorders to common 
mental illnesses like depression and anxiety disorders, which are also 
associated with high disabilities among  patients.  
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         The prevalence rates of depression and anxiety not only vary among the 
general population but also vary in the same population from time to time. 
Depression and anxiety have been reported to be associated with chronic 
medical illnesses.1  The odds for a specific mental  health disorder (mostly 
depression) are increased with systemic hypertension (Wells et al., 1989), 
chronic pulmonary  diseases ( Wells et al., 1988 ; Ede, Ijzermans & Brouwer, 
1999) and diabetes (Anderson, Freedland, Clouse, & Lustman, 2001;  
Garvard, Lustman, & Clouse, 1993;  Popkin, Callies, Lentz, Colon, & 
Sutherland, 1988; Lustman & Clouse, Griffith, Carney, & Freedland, 1997) . 
Depression  and anxiety caused by chronic diseases often make the 
condition worse. When depression or anxiety  is  comorbid  with any of 
chronic medical disorders, there is additive functional impairment and 
increase in the symptom burden which leads to increase in  medical costs and 
to impair adherence , functioning , self care  and quality of life.2  Depression, 
in particular, is associated with worse functional outcomes for patients  with  
chronic physical illnesses. Comorbid depression and anxiety is a risk factor 
for increased severity of the chronic illness because of non-adherence with the 
treatment and related complications and is also associated with increased 
frequency of hospitalizations, increased morbidity and   increased mortality. 
The  associated   depression  and anxiety  in  chronic medical  illnesses  
like  diabetes  mellitus, systemic  hypertension  and   chronic  obstructive  
pulmonary  disease   have  a  large  impact  on  
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(i) economic issues as they cause higher health care costs in chronic 
physical illnesses. 
(ii) maladaptive effects on chronic illnesses like amplification of  
symptoms burden, increased adverse health behaviors, decreased self-
care and  decreased adherence to medical regimens by adversely 
influencing expectations and benefits about efficacy of treatment 
(iii) Morbidity and mortality          and 
(iv)  Treatment implications. 
So, the prompt diagnosis of depression and anxiety in chronic diseases 
is mandatory in optimizing the management and   in understanding  the cause 
of the illness. 
          Diabetes mellitus is a syndrome of disordered metabolism, usually due 
to a combination of genetic and socio-environmental causes, due to defects in 
either insulin secretion or insulin action resulting in abnormally high blood 
sugar levels. Diabetes is a chronic medical illness which needs lifelong 
treatment either with dietary modifications or medication , in order to prevent  
or manage  its  complications.  
          According to International Diabetes Federation (IDF), India has the 
largest number of diabetic patients globally, and now, the number of diabetic 
patients in India is around 40.9 million and it is expected that, there will be 
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69.9 million diabetic population in India by 2025. (Diabetes Atlas – 6th  
edition).  India is the leading country in having highest number of diabetic 
patients among world population and so it is being termed as the “diabetes 
capital of the world”. 
         In India, there have been consistent reports of differences in the 
prevalence of diabetes mellitus between urban and rural population. The 
ICMR study reported that the prevalence of diabetes in urban areas was 2.1 
per cent and in rural areas was 1.5 per cent, where as an another study showed 
that threefold increase in prevalence of diabetes among urban population    
(8.2 % ) than the rural population (2.4%).  
According to the WHO-ICMR national NCD (Non Communicable 
Diseases) risk factor surveillance at 2006, a surveillance was conducted in 5 
States of India, in a different geographical locations (which includes northern, 
southern, eastern and western/central India)  and it indicated that the 
prevalence  of diabetes were 7.3% among urban people, 3.2% among by peri-
urban area and  3.1% among rural population.3  
         The Chennai Urban Rural Epidemiology Study (CURES) reported that 
the prevalence of Impaired Glucose Tolerance was 10.6 % (age - 
standardized: 10.2%) and that of diabetes mellitus was 15.5 % (age - 
standardized: 14.3%). Between the period of 1989- 1995 , the prevalence of 
diabetes mellitus was increased by 39.8% (From 8.3% to 11.6%)  in Chennai 
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and in between period of 1995 - 2000 the prevalence rate  increased by       
16.3 % (From 11.6% to 13.5%) and between the period of 2000 - 2004, the 
prevalence rate further increased to 6.0% (From 13.5% to 14.3%). These 
results  show that in Chennai itself within the period of 14 years, the 
prevalence of diabetes mellitus increased markedly to 72.3%.4 
          In  clinical  practice, identification  of  psychiatric  co-morbidity  like  
depression  and anxiety in  diabetes is often overlooked for a variety of 
reasons : societal disapproval of psychiatric illness, complicity between 
physicians and patients not to discuss psychiatric symptoms, and wrongly 
considering co morbid depression and anxiety as a ‘ normal consequence of 
difficult medical illness’.5 
       The comorbid depression or anxiety associated with diabetes can 
worsen the clinical outcome of the disease and it may be due to the fact that 
depression and anxiety would affect the treatment adherence and self care 
regimes of the patients. Similarly, uncontrolled diabetic status might lead to 
or aggravate depression and anxiety and it is due to the effects of diabetes 
over the central nervous system functions directly or  through its  indirect 
effects  on complications , functional impairment or decreased quality of life. 
Among South Asian population, Systemic hypertension emerges as the 
third leading risk factor for disease burden.6  Hypertension (HTN) evolves as 
a major  public health issue on healthcare systems in India.7 Systemic 
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hypertension is   the important causative factor for 24% of all deaths due to 
coronary heart disease (CHD) and 57% of deaths due to stroke  in India.8 
According to WHO reports, systemic hypertension is one among the risk 
factor in premature deaths worldwide .9      
         According  to worldwide data  analysis of the global burden of 
hypertension, 20.6% of  men and 20.9% of  women in India  were found to 
have  hypertension, in 2005.10  The percentage of hypertension may increase 
up to 22.9 for  men and  23.6  for women in India by 2025.11  The prevalence 
of hypertension is 25% in urban areas and 10% in rural people in India.12 
According to the WHO (2008), the prevalence of systemic hypertension in 
India was 32.5% (33.2% in men and 31.7% in women)  
        Among hypertensive patients all over the world, 17.8% of them reside in 
India as per Global Burden of Hypertension (2005),11 the Global Burden 
Diseases (2010) study6 and WHO (2011) NCD India specific data.  The 
prevalence of hypertension was increased multiple folds from 13.9 to 46.3% 
in urban population and from 4.5 to 58.8% in rural areas which was reported 
in a review study of studies published between 1969 and July 2011.13. One-
third of urban adult Indians and close to one fourth of rural adult Indians are 
hypertensive. Hypertension was estimated to be 20% among adults population 
all over the world.14 
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        Because hypertension is one among the most prevailing chronic 
conditions, it is necessary to investigate the prevalence of anxiety and 
depression in these patients.  There is strong evidence that the co morbidity 
between systemic hypertension and mental illness is very high. The 
relationship between systemic hypertension and depressive symptoms is a 
complex issue. The course of the   hypertension can be negatively affected 
and greatly influenced by depression and anxiety.  The sympathetic nervous 
system over activity and genetic predisposition are the underlying 
mechanisms in explaining the co morbidity of depression and systemic 
hypertension.  
          Chronic obstructive pulmonary disease (COPD) is the fourth leading 
cause of death worldwide and a  major cause of chronic morbidity and 
mortality throughout the world.15  COPD   includes diseases  that were 
previously known as chronic bronchitis and emphysema.  
         The British Medical Research Council (BMRC) defined chronic 
bronchitis as “daily productive cough for at least three consecutive months for 
more than two successive years. The definition of emphysema put forth by the 
National Heart, Lung and Blood Institute in 1984 is as “a condition of the 
lung characterized by abnormal, permanent enlargement of airspaces distal to 
the terminal bronchiole, accompanied by the destruction of their walls, and 
without obvious fibrosis”.  COPD has abnormalities of both airway and 
airspace. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
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recently defined COPD as “a common preventable and treatable disease 
characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways 
and the lung to noxious particles or gases.  
         The prevalence of COPD varies widely across countries and this 
variation is due to the method of classification and diagnosis of COPD. The 
global prevalence of physiologically defined chronic obstructive pulmonary 
disease (GOLD stage 2 or more) in adults aged ≥40 yr is approximately 9-10 
percent.16 The overall prevalence of COPD of GOLD stage II or higher was 
10.1 per cent and the prevalence was 11.8 per cent for men and 8.5 per cent 
for women (The Burden of Obstructive Lung Disease (BOLD) study).17 
          The prevalence of COPD was 3.36 per cent in males and 2.54 per cent 
in females in a study. 18. The prevalence in New Delhi in 1977 was 8.1 per 
cent in men and 4.6 per cent in women19 and the prevalence was 3.9 per cent 
in women and 6.2 per cent in men  in rural area, and 1.6 and 4.2  per cent, 
respectively in urban area in 1993.20  The  prevalence of COPD is 1.9 per cent 
in males and 1.2 per cent in females in Chennai.21. Ray et al in 1995 found 
that the prevalence of COPD was 4.08 per cent in males and 2.55 per cent in 
females from south India. There are wide variations in the prevalence of 
COPD in Indian subcontinent.22 
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           Anxiety and depression are highly prevalent co morbidities in Chronic 
obstructive pulmonary disease.23 Investigating depression and anxiety in 
COPD  is difficult due to the variability in presentation and the significant 
overlap of symptoms between COPD, depression  and  anxiety  and the  
subjective nature of the diagnostic process.24  The  anxiety and depression in 
COPD were associated with poor course of  the disease, poor  quality of life 
and increased burden of symptoms , health-care utilities, and even mortality.25 
The psychiatric symptoms themselves can be  aggravated  by patients’ 
disabilities and, in turn, they can magnify  patients’ COPD symptoms. Thus, 
detecting depression or anxiety in COPD patients is of great importance. 
Considering all the above factors it is necessary to study the prevalence 
of psychiatric co morbidities of depression and anxiety in chronic illnesses 
like Diabetes mellitus, Systemic hypertension and Chronic obstructive lung 
diseases and estimated in this study. 
 
 
 
 
 
 
 REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
DEPRESSION: A VIGNETTE  
According to ICD – 10, an individual is said to be in depression either 
mild, moderate or severe who usually suffers with typical symptoms of 
depressed mood, loss of interest and decreased energy that may lead to 
increased fatigability and decreased activity.  
The various other symptoms are  
(1) Decreased attention and concentration,  
(2) Decreased self – esteem and self – confidence,  
(3) Guilty feelings and worthlessness  
(4) Negative view about the future,  
(5) Self – harm or suicidal thoughts,  
(6) Sleep disturbances,  
(7) Lack of appetite. 
Depression can be categorized in to mild, moderate and severe, 
according to the number of typical symptoms and the various other 
symptoms. For the diagnosis of depression, these symptoms should persist for 
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about 2 weeks and cause significant impairment in social and occupational 
functioning.  
Depression can occur alone or as a part of Bipolar disorder. If it occurs 
alone, then it is known as Unipolar depression. Depression is more common 
in women than men with the ratio of  2 : 1.  At least 25 % of the patients had 
one or more precipitating events. There is also a diurnal variation in the 
symptoms: the symptoms worse in the morning. Approximately 75% of 
depressed patients experienced sleep disturbances, either insomnia or 
hypersomnia. About 60 % of the depressed patients have suicidal ideation and 
15% commit suicide. 
ANXIETY: A VIGNETTE  
Most of us have experienced the anxiety symptoms but for a definite 
diagnosis, it should be clinically significant, must be severe enough to cause 
significant distress, and / or it must be markedly interfere our day–to–day 
lives and socio occupational functioning.  
Anxiety is a state which has many effects. It influences the cognition 
and produces the perceptual distortions. There is a difference between fear 
and anxiety. In fear, there is an appropriate response to a known threatening 
stimuli, where as in anxiety there is also a response to a threat which is not 
known, not certain or disagreeable.  
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Most of the symptoms of anxiety are dreadful which are accompanied 
with somatic complaints and autonomous nervous system hyperactivity such 
as tachycardia, palpitation, sweating, dry mouth, etc.,. Anxiety accompanies 
with psychological symptoms such as feeling of dread, difficulty in 
concentration, insomnia, decreased libido, lump in the throat (Globus 
Hystericus ) and stomach upset (Butter flies).  
DSM-IV eliminated the term “Neurosis” in its diagnostic manual, but 
still it is retained in the ICD – 10, as Neurotic, stress related and somatoform 
disorders (F 40 – F 48). It may be convenient to divide the anxiety and stress 
related disorders in to 3 categories, because of the acceptable quality of the 
symptoms in each category.  
1. The common neuroses:  
Anxiety / Panic disorders; e.g. Panic disorder,  
Agoraphobia,  
Generalized Anxiety Disorder,  
Specific Phobia,  
Social Phobia,   
Hypochondriasis.  
(Illness anxiety disorder in DSM 5)  
Stress related disorders: e.g. Acute stress reactions,  
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Adjustment disorders,  
Post Traumatic Stress Disorder (PTSD).  
Obsessive compulsive disorders (Separate entity in DSM – 5)   
2. The Unusual Neuroses:  
Anxiety / Phobic disorders e.g. “ non – understandable” phobias  
 Dysmorphophobia.  
Hysterical conversion disorder,  
Dissociation /Depersonalization – Derealization disorders,  
Somatoform disorders.  
3. “Culture specific” disorders:  
Chronic fatigue syndrome / Eating disorder,  
Other “culture bound” disorders.  
DEPRESSION IN  DIABETES  MELLITUS  PATIENTS 
          According to the World Health Organization (WHO) , depression is a 
significant health concern causing 12% total years lived with disability. 
Approximately 43 million people worldwide with diabetes have symptoms of 
depression.26. In people with diabetes, the prevalence of clinically relevant 
depressive symptoms is between 26 – 31 % and that of major depression 
between 9 – 11 %.27  
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Diabetes increases twice the prevalence of depression. These increased 
rates of depression among diabetic population have been confirmed in 
multiple studies28 in South Asia. The earlier hypothesis observed that 
depression in diabetes may be the result of psychosocial stress of having a 
chronic illness29. Another hypothesis also known as the common soil 
hypothesis posits that association between depression and diabetes results 
from factors affecting both disorders. 
Current research also supports a contribution of biological changes in 
diabetes, such as functional, structural and neurochemical changes in the brain 
regions responsible for the affect and cognition in both type 1 and type 2 
diabetes that may increase the risk of depression. 30 
          Depression in diabetes is persistent and /or recurrent. In longitudinal 
and follow up studies, the rates of depression persistence or recurrence have 
been reported to range widely, between 11.6 % and 92 %, depending on 
sample sizes, diagnostic criteria of depression and depression classification. 
PREVALENCE OF DEPRESSION IN TYPE 2 DIABETES  MELLITUS 
CONTROLLED STUDIES:   
Controlled studies which have used the control groups may allow us 
for better comparisons. In a meta – analysis study by Ali S et al in 2006 31,  
10 controlled studies including 7 community based studies ( Palinkar et al, 
1991; Viinamaki et al, 1995, Amato et al, 1996; Eaton et a1996;  
15 
 
Black et al,1999; Gregg et al, 2000; Pouwer et al, 2003), 2 primary care based 
studies ( Janet Thomas et al, 2003; Nicolas et al,2003) and 1 secondary care 
based study (Saeed and Al-Dabbagh et al, 2003) were reviewed.  Various 
assessment scales were used in these studies. BDI – Beck Depression 
Inventory, a self report questionnaire used in Palinkar et al, 1991, CES-D 
(Centre for Epidemiological Studies for Depression) Scale was used in Black 
et al, 1999; and Pouwer et al, 2003. 
This meta-analysis review inferred the prevalence of depression among 
type 2 diabetes mellitus patients when compare with non diabetic individuals. 
(Odds Ratio; 1.77, 95% CI; 1.5 – 2.0). These findings were consistent when 
the rates were determined by gender, sample source, depression assessment 
methods and by geographical location. According to this meta-analysis, the 
overall prevalence of depression among type 2 diabetic patients was 17.6%, in 
which the female patients had a higher prevalence (23%) than male patients 
(12.8%).  
Anne Engum et al in 2005 32 conducted a large population study and 
found that, the prevalence of depression among type 2 diabetic patients was 
19% and in the non diabetic control groups the prevalence was 10%.  
Shamsaei et al in 2006 33conducted a study in Iran and found that mean Beck 
depression score among type 2 diabetic patients was more (18.6) than the non 
diabetic control groups (9.1).  Mary de  Groot  et al in 2007 34,conducted a 
community based study in type 2 diabetes mellitus patients and revealed that 
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31% of the participants showed a clinically significant depression in Beck 
Depression Inventory Scale.   
UNCONTROLLED STUDIES:  
In a meta - analysis study of Anderson et al in 2001 35; he reviewed 22 
uncontrolled studies to estimate the prevalence of depression in diabetic 
patients. According to this study the overall prevalence of depression among 
diabetic patients was 29.7%. Among the 22 uncontrolled studies, 5 of them 
(Biglan et al, Connell et al, Geringer et al, Marcus et al 36 and Nalibott et al ) 
evaluated the prevalence of depression in type 2 diabetic patients which 
showed that the prevalence of depression in type 2 diabetic patients was 
higher (Mean: 33.8%, Range: 18.8% - 47%) than the type 1 diabetic patients 
(Mean: 21.2%, Range: 11.5% - 42.4%).  
Among the 22 uncontrolled studies, 5 of them estimated the prevalence 
of depression in male and female diabetic patients separately (Bailoy et al, 
Haire – Joshu et al, Naliboff et al, Peyrot et al 37 and Slawson et al) which 
showed that the prevalence of depression was greater in females (33%) than 
in males (20.7%).  
         In a recent study at Malaysia, Kurubaran Ganasegeran et al in 2014 38 
demonstrated the factors connected with depression and anxiety among type 2 
diabetic patients. They conducted a descriptive cross – sectional study in a 
single centre and found that, among 169 type 2 diabetic patients (men, n=99; 
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women, n=70), depression present in 68 patients (40.3%), and anxiety present 
in 53 patients (31.4%). Multivariate analysis of this study shows that, the age 
of onset, ethnicity, monthly income and the complications associated with 
diabetes were significantly influenced the causation of both depression and 
anxiety among the type 2 diabetic patients. 
INDIAN STUDIES: 
Poongothai S et al 39 and her colleagues at 2009, conducted a 
population based study to estimate the prevalence of depression in an urban 
south Indian population –Prevalence of depression was assessed by using 
Patient Health Questionnaire (PHQ) - 12: a self – reported questionnaire, and 
found that, the overall prevalence of depression was 15.1%, and the 
prevalence of depression was higher in females (16.3%) than in males 
(13.9%).  
Chandran et al in 2002 40 conducted a study, to estimate prevalence of 
depression among rural and low socio economic status women  
(359 participants) and found that overall prevalence of depression among 
them was 11%.  
         Biswas et al in 2009 41conducted a door to door survey to estimate the 
prevalence of depression in elderly individuals (204 participants) and found 
that the prevalence of depression among them was 31.5%. 
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         Amit Raval et al in 201042, in  Chandigarh, India conducted a study to 
estimate the prevalence and determinants of depression among type 2 diabetic 
patients and found that, among 300 type 2 diabetes mellitus patients (147 
male patients and 153 female patients ), 68 patients (23%) had major 
depression, 54 patients (18%) had moderate depression and 178 patients 
(59%) had no clinically significant depression. They also found that the age of 
onset, duration of diabetes, obesity, glycemic control and the diabetic 
complications having an impact in the causation of depression in type 2 
diabetic patients. 
         In a recent study of Nitin Joseph, Bhaskaran Unnikrishnan, 
Y.P.Ragavendhra Babu M, Shashidhar Kotian, and Maria Nelliyanil et al 
in 2013 43; they conducted a study to estimate the proportion and determinants 
of depression in type 2 diabetic patients in various tertiary care hospitals at 
Mangalore, South India. Among the 230 type 2 diabetic patients (119 male 
patients, 111 female patients), 71 patients (30.9%) met the criteria of 
moderate depression, 33 patients (14.3%) met the criteria of severe depression 
and the remaining126 patients did not have any clinically significant 
depression. They also found that, the older age, low socio economic status, 
female gender, unskilled & retired employment status, obesity, daily 
medications and the complications of diabetes, were markedly associated with 
the causation of depression in type 2 diabetic patients. 
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PREVALENCE OF ANXIETY IN DIABETES MELLITUS:  
Most of the studies in Diabetes focus on the psychiatric disturbance of 
depression, where as only few studies demonstrated the anxiety disorders in 
Diabetes mellitus patients.  
Kaufman et al 44 and Roy A et al, demonstrated that, the co - morbid 
Anxiety disorder with Diabetes lead to a symptom severity and persistence of 
symptoms and greatly impair the individual role in the social and 
occupational milieu.  
Barker et al in 2008   demonstrated the association of anxiety disorders 
in type 2 diabetes mellitus patients. In this study, a structured diagnostic 
interview method like DIS – DSM IV (Diagnostic Interview Schedule for 
DSM – IV) was used. They found that the overall life time prevalence of 
anxiety disorder among diabetic patients was 19.5%, when compare to the 
non – diabetic individuals (10.9%).  
Grisby et al in 2001 45 conducted a systematic review on 18 studies 
regarding the prevalence of anxiety disorders in an adult population with 
diabetes. He found that, the symptoms of anxiety were present in about 40% 
of the diabetic patients. He also found that there is an significantly elevated 
anxiety symptoms present among female diabetic patients (55.3%) than the 
male diabetic patients (32.9%) and there is an increased symptoms of anxiety 
present among type 2 diabetic patients (42.2%) than with type 1 diabetic 
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patients (41.3%). Among the 40% of diabetic patients presented with anxiety 
symptoms, while applying definite diagnostic criteria only 14% of the 
diabetic patients were qualified for the definite diagnosis of Anxiety 
disorders.  
Hermanns et al in 200546 carried out a study to estimate the 
prevalence of anxiety symptoms in a secondary care clinic and found that, 
19.3% of the diabetic patients had anxiety symptoms and 5.9% of them were 
fulfilling the criteria of anxiety disorders.  
Lloyd et al in  200047 demonstrated that 28% of the participants had 
moderate to severe levels of anxiety or depression or both. Shaban et al in 
2006, found that 36% of the study participants had anxiety symptoms, and 
also found that, there is an elevated severe anxiety symptoms present among 
female diabetic patients.  
Janet Thomas et al in 200348, conducted a comparative study in a 
primary care patients who were diagnosed as type 2 diabetes mellitus, to 
evaluate the 12 months prevalence of depression and anxiety and found that 
11.7% of the T2DM patients had anxiety disorders and 13% of the T2DM 
patients had mixed anxiety and depression disorder. This study shows that, 
type 2 diabetes mellitus increases the probability of acquiring anxiety 
symptoms by an Odds ratio of 2.26. (1.28 – 4.01, p value; 0.005).  
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In a recent study, Carlos Tovilla-Zarate et al in 2012 49 conducted a 
study to estimate the prevalence of anxiety and depression among T2DM 
patients in an outpatient set up in the Mexican population. The prevalence of 
anxiety was 55.10% (95% CI; 44.48 – 52.06) and also found that, occupation 
and diabetic complication were the associating factor for anxiety in type 2 
diabetic patients.  
In a recent study at Malaysia, Kurubaran Ganasegeran et al in 
201450, demonstrated the factors connected with depression and anxiety 
among type 2 diabetic patients. They conducted a descriptive cross – sectional 
study in a single centre and found that, among 169 T2DM patients (men, 
n=99; women, n=70), anxiety present in 53 patients (31.4%). Multivariate 
analysis of this study shows that, the age of onset, ethnicity, monthly income 
and the complications associated with diabetes mellitus were significantly 
associated with the causation of both depression and anxiety among the type 2 
diabetic patients.  
        Khuwaja AK et al in 2010 51 conducted a multi – centre study at 
Karachi, Pakistan, to evaluate the prevalence of anxiety and depression 
among T2DM patients and found that, among the 889 participants 57.9% of 
the type 2 diabetic patients had anxiety symptoms (95% CI = 54.7%, 61.2%).  
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DEPRESSION AND ANXIETY IN SYSTEMIC HYPERTENSION 
         Systemic hypertension is one among the most commonly prevailing 
chronic illnesses in the community and psychiatric co morbidities of 
depression and anxiety are also more prevalent in hypertensive patients. 
OVERACTIVE AUTONOMIC NERVOUS SYSTEM   
          Plenty of studies have been done and a theory has been propounded 
with evidence that a possible overactive sympathetic response of the 
autonomic nervous system and genetic involvement form the intrinsic 
mechanisms which define a relation between hypertension and depression and 
anxiety, in which depression largely has a negative influence on the course of 
hypertension.52 
         The abnormality in the sympathetic division of the autonomic nervous 
system in depressive patients, exclusively with regard to reduced vagal 
control and an increase in sympathetic activity, has been evidenced by studies 
which reported the presence of elevated levels of nor epinephrine and its 
significant CNS metabolite 3-methoxy 4-hydroxyphenylglycol  in plasma, 
CSF and urine samples of depressive patients.53,54,55.  
         A distinctive reduced level of cholinergic outflow with increased 
activity of the alpha and beta adrenergic systems was found to characterize 
the autonomic profile of depressive patients, further evidenced by a decreased 
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variability in heart rate suggesting a reduced activity of the parasympathetic 
system and an over active sympathetic system in patients with depressive 
disorder.56,57 
         It is possible that several other explanations may exist to define the 
relation between blood pressure and depression with an overactive 
sympathetic system not being the sole one; however it was proposed by 
Seiver et al 58 that the increased understanding in the influences exerted by 
neurotransmitter systems in mood disorders are possibly due to failure of the 
regulation of the systems, and not just a simple decrease or increase in their 
activity, and such dysfunction in the noradrenergic system regulation was 
expected to negatively affect the individuals affective response to internal and 
external stimuli. 
         Studies hypothesized a possible relation between depression and an 
abnormality in the circadian regulation of blood pressure evidenced by the 
depressive symptoms exhibited by 126 men, devoid of any psychiatric illness 
and not on any medication, associated with an increased ratio of night/day 
systolic blood pressure. Disturbances in the regulation of hormones and 
dysfunction of the Autonomic Nervous System have been advocated as 
explanations for the above results.59 
         A possible relation between hypertension and depressive 
symptomatology were evidenced by studies conducted in patients of 
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borderline hypertension, who demonstrated an increased range of scores in 
negative affect post tasks.60.  
         A study conducted by Rabkin et al 61, evidenced the presence of a three 
times higher rate of major depression in hypertensive patients and it was 
attributed by elevated sympathetic tone and increased secretion of adreno 
cortico tropic hormone and cortisol. In the study conducted over a period  of 7 
days in 54 subjects by monitoring their blood pressure ranges over a period of 
24 hours each day, it was found that a positive relation existed between high 
levels of diastolic (P=0.030) and systolic (P = 0.037)  blood pressures and a 
depressive mood .62 
         The genetic influences form an important etiology in mood disorders 
was evidenced by several  family, adoption and twin studies, with similar 
others advocating a ‘shared genetic-vulnerability’ explanation to define the 
association between hypertension and depressive disorders. 
         Increased levels of symptoms of depression was shown to exist with 
higher risk of stroke in elderly hypertensive patients as evidenced by 
epidemiological studies conducted  to evaluate the longitudinal association 
between stroke, cardiovascular related mortality, BP control and depressive 
symptomatology in elderly patients, with such association especially in 
women considered to be a function of BP control.63 
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          Several studies advocated that depressed patients showed an increased 
susceptivity to activation of platelets possibly being the intrinsic mechanism 
involved in the higher risk of cerebrovascular disease , ischemic heart disease 
and  post myocardial infarction in such patients.64 . Another theory has been 
propounded based on the evidence offered by several brain imaging studies, 
which demonstrated an increased rate of ischemic abnormalities in depressive 
disorders occurring late in life, that hypertension could serve as a risk factor 
in development of the same.65 
           Associations between hypertension and anxiety have been 
hypothesized for decades. The possible relationship between hypertension and 
anxiety are increased autonomic nervous system functions via hypothalamic-
pituitary axis  and subsequent increase in circulating catecholamines. This 
association holds across the spectrum of anxiety disorders.  In hypertensive 
patients , the outcome is negatively affected by anxiety. The underlying 
mechanisms between negative effects of anxiety and hypertension and 
cardiovascular diseases are possible arousal of sympathetic nervous system, 
elevated inflammatory markers and defect in endothelial function .66 
PREVALENCE OF DEPRESSION AND ANXIETY IN  
HYPERTENSION 
         In a population-based estimation study conducted in sub-Saharan Africa, 
it demonstrated an association between hypertension and mental disorders and 
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8.1% and 4.9% were found to have a 12-month anxiety or depressive disorder 
in hypertensive patients, respectively.( Grimsrud A et al).67 
         Scherrer et al,68 reported that there are common genetic and 
environmental risk factors underlying hypertension , depressive symptoms 
and heart disease. They conducted an association study with 6,903 male‐male 
twins from the Vietnam Era Twin Registry and found that, of the total 
variance in depression, 8% was common to hypertension and heart disease, 
7% of the variance in hypertension was common with depressive symptoms 
and heart disease, and 64% of the variance in heart disease was common with 
depressive symptoms and hypertension and suggesting that there are common 
genetic factors that predispose individuals to hypertension and depression 
         In a review study,  Huapaya, L et al 69  revealed that many studies 
indicated that the prevalence of depression  is high in 37% in hypertensive 
patients compared to a prevalence of 4–22% in the general population. In a 
community based study in Hong Kong, they concluded that hypertension is 
associated with anxiety but not depression. Vetere G et al 70 observed that  
higher frequency of anxiety symptoms  in  hypertension  than in the control 
group (p <0.001) . 
         Wei and Wang 71 found that anxiety symptoms were prevalent in 12% 
of known hypertensive patients. The occurrence and severity of Anxiety 
symptoms were associated with the duration of hypertension, female gender 
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and history of hospitalization in patients with hypertension. Thombre72 and 
colleagues found that pre pregnancy depression or anxiety symptoms were 
associated with hypertension during pregnancy.  
DEPRESSION AND ANXIETY IN CHRONIC OBSTRUCTIVE 
PULMONARY DISEASES 
              Chronic Obstructive Pulmonary Diseases are at an increased risk of 
developing depression. It could be attributed to genetic vulnerability to mood 
disorder, the environmental factors and the direct neuropsychiatric 
consequences of chronic pulmonary diseases. 
GENETIC FACTORS 
        This risk due to genetic vulnerability is validated by  twin and  adoption 
studies. The twin studies infer a concordance rate of 50% in monozygotic 
twins, 10%–25% in dizygotic (Kaplan and Sadock 1988; Kendler et al 2006; 
Sullivan et al 2000). The risk of an adolescent in turning into chain smoker is 
directly proportional to the number of each additional copy of an identified 
allele (DRD2A1) for a subtype of a dopamine receptor and the depressive 
symptoms are augmenting the effect.( Audrain-McGovern et al 2004).73 
SOCIAL FACTORS 
         The depression in chronic medical illness leads to loss of functionality 
with an attributable risk at 34% ( Dunlop et al 2004 ).74 The functional 
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impairments caused by depression include decline in daily activities, 
difficulty in performing previous role in family, social  and occupational life 
and inability to follow their interests and hobbies. The social support available 
to the patients will help them to cope with the stressful conditions due to 
chronic diseases. Lesser the social support,  the more  is the patients’ 
vulnerability to  depressive symptoms.. ( McCathie et al 2002)75.  Loneliness, 
poor functionality and poor reversibility of FEV1  contributes to depression.  
(van Manen et al 2002 ).76 
NEUROPSYCHIATRIC FACTORS 
          The concentration of subcortical hyperintensities (SH)  in MRI brain is 
found to be associated with higher proportion in depression.77 Videbech 1997 
78 inferred in a meta-analysis  that a common odds ratio  for subcortical hyper 
intensities and major depression was 3.2 (95% CI 2.11–4.82). There is strong 
evidence of an association between subcortical hyperintensities and late-onset 
depression, as well as between COPD and an increased severity of subcortical 
hyperintensities  (van Dijk et al 2004). 79 The accumulation of subcortical 
hyperintensities would be due to the changes in  microvasculature and 
biochemical alteration by depression and COPD.  
         The biomarkers of oxidative damage are considerably elevated in 
depression. A study by Forlenza and Miller 2006 80, showed a direct 
correlation with levels of 8-hydroxy-2′-deoxyguanosine with the severity of 
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depression and levels of oxidative stress with severity of depression. 
Depressed mood is the sequelae of recurrent nocturnal hypoxaemia . In both 
depression and COPD, micro vascular thrombosis are caused by more 
pronounced platelet activation (Davi et al 1997).81 
 Anxiety is  more commonly associated with COPD. The common 
mechanisms underlying the high association of anxiety with Chronic 
pulmonary obstructive disease include factors related to dyspnoea and 
smoking.  
          Dyspnoea is the most distressing symptom in COPD patients. 
Individuals with COPD experiencing severe dyspnoea are being associated 
with anxious feelings and  they describe anxiety features during disease 
exacerbations. Furthermore, anger outbursts and frustration are triggering 
factor for anxiety, which causes breathlessness. Therefore, it is very apparent 
that  the complex association  between breathlessness and anxiety contribute 
to the increased prevalent rate  of anxiety symptoms  in COPD.82 
         The variables associated with Depression and Anxiety in patients with 
COPD are severe dyspnea , physical disability, presence of co morbidity ,  
poor quality of life , living alone, percentage of predicted FEV1 < 50% , long-
term oxygen therapy,   female gender,  current smoking and  low social 
economic status. 
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PREVALENCE OF DEPRESSION AND ANXIETY IN COPD 
         In a case control study,  Gehan Elassal et al 83 found that in a sample of 
80 patients,  55% of them have psychiatric illnesses and depression was found 
to be around 42.5% in COPD patients  and  anxiety  was found to be  22.5% 
in COPD patients.  
Light RW  et al 84  found  that there was significant correlation 
between depression and anxiety scores  and 42 % of the patients had 
significant depression, while only 2 % of the patients had significant anxiety. 
         In a prevalence study of depression and anxiety in COPD patients, 
Regvat et al 85 found that 50% of the  patients   of COPD study group showed 
anxiety and/or depression. In a similar study by D. Janssen et al 86 , the mean 
anxiety scores was 7.6 points and mean depression scores was 7.2 points , in a  
study conducted with 701 patients. 
          K. Roundy at al 87 stated that depression and anxiety disorders are 
recognized about 49 % of the patients in COPD in primary care setting. In a 
Korean study, Y.Ryu et al 88 found patients with chronic respiratory diseases 
have increased association for depression and anxiety particularly in those 
having decreased lung function with airflow limitations. The incidence of 
anxiety and depression symptoms is higher in COPD patients with more 
hospitalizations and age and gender has no significance in depression.89  
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         In another study, depression and anxiety were more frequent in patients 
with chronic bronchitis than those without chronic bronchitis  and  in female 
gender  and those having co morbidities. 90 In stable COPD, the prevalence of 
clinical depression ranges between 10% and 42%, while that of anxiety ranges 
between 10% and 19%.91 Depression occurs in 7 to 42% of patients with 
COPD, and a strong association was found between COPD and depression 
which was evident from  four controlled studies  and   three of six non-
controlled studies and it also revealed  the prevalence of depression was high  
in COPD compared with general population. 92 
         Multiple studies have found increased prevalence of depression in 
patients with COPD than in control subjects. Yellowlees 93 found that 34% 
had an anxiety disorder and 16% had depression in a study with 50 inpatient 
COPD patients.  Dowson et al 94 found anxiety in 50% and depression in 28% 
of 72 patients with COPD hospitalized for rehabilitation services. 
  
 AIMS  AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
1) To estimate the prevalence of Depression and Anxiety in Type 2 
Diabetes Mellitus, Systemic Hypertension and Chronic Obstructive 
Lung Disease. 
2) To understand Socio demographic characteristics of the patients with 
DM, COPD, SHT and anxiety and depression. 
3) To evaluate the difference between the presentation of anxiety and 
depression in the study groups. 
4) To compare the prevalence of depression and anxiety among patients 
of DM, SHT and COPD . 
 
 
 
 
 
 
 
 MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
STUDY DESIGN 
Cross sectional study with internal comparison 
STUDY  SETTING  
The  study was conducted at the  Diabetology / Hypertension / Chest 
diseases Out patient department at Government Stanley Medical College 
Hospital, Chennai.  It is a tertiary care teaching institute where patients come 
from northern part of Chennai, Tiruvallur  District and from southern districts 
of Andhra Pradesh.  
STUDY PERIOD 
6 Months 
STUDY POPULATION 
The study population includes patients attending out - patients 
department of  Department of  Diabetology / Systemic Hypertension OPD / 
Department of TB & Chest diseases.  
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SUBJECTS OF STUDY 
Group I 
Diabetic  patients who have been diagnosed  and  registered in 
Department of  Diabetology. 
Group II 
Patients who have been diagnosed  as Hypertensive  and  registered in 
Systemic Hypertension OPD 
Group III 
Patients who have been diagnosed  as Chronic Obstructive Pulmonary 
Disease  (COPD) and  registered in Department of  TB  and  Chest Diseases. 
INCLUSION CRITERIA  
1.  Patients diagnosed as Diabetes mellitus  /  Systemic Hypertension  /  
COPD and registered in the respective departments. 
2.  Age > 30 years and < 50 years  
3.  Patients of both genders with  duration of  illness ( DM / SHT / COPD)  
more than 5 years 
4.  Informed consent 
5.  Patients on regular follow-up 
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EXCLUSION CRITERIA 
1.  Presence of any other  associated Co-morbid  chronic physical 
disorders with the primary  illness..  
2.  Past or present history of any mental illness.  
3.  Family History of any psychiatric illness 
4.  Age Below 30 years or above 50 years 
5.  History of substance abuse 
SAMPLING 
    For each group, consecutive cases from respective department OPD 
who satisfied Inclusion criteria were taken. 
VARIABLES  STUDIED  
Socio economic Variables- Age, Sex, Religion, Family, Domicile, 
Marital status, Education, Occupation, Income And Socio economic status    
Clinical Variables - Duration of chronic physical illness,  Complication of the 
illness, number of hospitalization, medication adherence, depression and 
anxiety symptoms. 
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STUDY PROCEDURE 
1.  After obtaining informed consent from patients with DM / SHT / 
COPD attending the respective speciality OPD, they will be 
interviewed and assessed using various scales. Data will be recorded 
for this purpose.  
2.  Information is obtained from patient, reliable informant, and from 
medical records.  
3.  Socio – demographic and medical details will be obtained using a semi 
structured questionnaire designed for this study. 
MATERIALS FOR THE ASSESSMENT 
1.  Socio – demographic pro- forma sheet designed for this study.  
2.  Beck depression inventory (BDI).  
3.  Hamilton rating scale for Anxiety (HAM-A).  
4.  Morisky Medication Adherence Scale : MMAS‐8 
BECK DEPRESSION INVENTORY (BDI). 
BDI95 is the one of the most important self - report rating scale which is 
a gold standard tool to assess the depression severity. BDI was developed by 
Beck et al, at 1961, and his original and an old BDI consists of 21 items, 
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which concern about various symptoms with varying degrees of severity and 
rated the scores as 0 – 3. BDI96 – II edition was released after the introduction 
of DSM – IV , which included some new items and excluded some items 
present in the previous scale, and make it more reflective towards DSM – IV. 
BDI – II consists of 21 items, with a total score ranges of 0 – 84. Scores of 0 -
10 considered as normal mood swings of ups and downs; considered as 
normal, the according to the scores, classified as mild to extreme depression. 
BDI was used in various studies because of its high reliability and consistent 
validity, and also the internal consistency of this scale is higher. Since this 
scale is having the advantage of time consumption, patient self reporting 
model, and the easy scoring of the severity make it a gold standard tool to 
assess the severity of depression.  
THE HAMILTON RATING SCALE FOR ANXIETY97 (HAM-A):  
This rating scale is administered by the clinician, and it is basically a 
semi – structured type to evaluate the anxiety symptoms. This scale evaluates 
symptoms alone and not for any specific disorders. It is one of the rating scale 
developed first to assess the severity of the symptoms. Still, it is used for 
clinical studies and for research purposes, because of it’s high reliability as 
well as it’s high validity. It also yields a high consistency. This scale is also 
used in the drug trials for the quantifying the outcome, in Generalized anxiety 
disorder. 
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This scale consists of fourteen entities, each of the entity is graded as 0 
to 4 (not present to severe), higher the scores more severe in the anxiety 
symptoms. The total score is ranges from 0 – 56, and the scores < 17 indicates 
mild severity, scores between 18 and 24 indicates mild to moderate severity, 
scores between 25 and 30 indicates moderate to severe anxiety symptoms, and 
the total scores more than 30 indicates very severe.  
HAM – A scale is a simple scale easy to administer within 20 to 30 
minutes. It is useful to monitor the improvement after initiation of drug 
treatment. This scale was translated in various languages, because of it’s 
acceptable inter – rater reliability 
MORISKY MEDICATION ADHERENCE SCALES: MMAS‐898 
This self-reported medication adherence scale was originally 
developed by  Prof.Morisky. This MMAS-8 was developed from a previously 
validated MMAS-4  scale. It was  supplemented with additional items 
considering  the circumstances surrounding adherence behavior. Each item is 
measuring a specific medication-taking behavior and not a determinant of 
adherence behavior.  
 
 
 OBSERVATION AND 
RESULTS 
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OBSERVATION AND RESULTS 
Socio-demographic characteristics 
The survey data were analysed to find out the age, sex, religion, family 
type, residence, marital status, education, occupation, income and socio-
economic status of the participants across three groups.  
The mean age of the participants (N=180) is 41.31 with a standard 
deviation of 5.19. Individual mean scores across patients of DM, SHT and 
COPD are presented in figure 1.  
 
Figure 1: Individual mean age in different study groups. 
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Sex distribution across DM, SHT and COPD 
Figure 2 depicts the distribution of males and females across DM, SHT 
and COPD. The males and females are equally distributed in DM and SHT 
groups whereas males predominate the COPD group. 
 
Figure 2: Sex distribution across DM, SHT and COPD 
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Religion 
Figure 3 illustrates the frequency distribution of religion among the 
study participants. Hindus were more in number. 
 
Figure 3: Frequency distribution of religion across DM, SHT and COPD 
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Family type 
Most of our study participants come from nuclear families, n=108 
[N=180]. Figure 4 shows the distribution of family type across the study 
groups. 
 
Figure 4: Frequency distribution of family type across  
DM, SHT and COPD 
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Domicile 
Urban population were more with 68.9% of the entire study 
population, N=180. Figure 5 demonstrates the residence of the study groups 
in percentage. 
 
Figure 5: Domicile of study groups 
 
70
70
66.7
30
30
33.3
0 10 20 30 40 50 60 70 80
DM
SHT
COPD
Domicile  in percentage
Rural Urban
44 
 
Marital status 
The marital status of the participants is given below in figure 6. Most 
of the participants were married n=156 while only 24 of them were 
unmarried. 
 
Figure 6: Marital status of the participants 
Groups Frequency Percent 
DM Married 51 85.0 
Unmarried 9 15.0 
Total 60 100.0 
SHT Married 54 90.0 
Unmarried 6 10.0 
Total 60 100.0 
COPD Married 51 85.0 
Unmarried 9 15.0 
Total 60 100.0 
 
Table 1: Marital status of the participants 
85 90 85
15 10 15
DM SHT COPD
Chart Title
Married Unmarried
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Education 
Forty-eight participants (26.7%) from the three groups were illiterate 
with no professionals in any of the groups. A small group of the participants 
were graduates or post-graduates. Rest of them were almost equally spread 
between primary school and diploma. 
 
Figure 7: Education of the participants 
10
5
5
8.3
10
20
20
25
15
20
5
15
16.7
30
15
25
25
25
COPD
SHT
DM
Education
Illiterate
Primary school
Middle school
High schoolMiddle school
Intermediate or post high school or diploma
Graduate or postgraduate
46 
 
Study Groups Frequency Percent 
DM Graduate or postgraduate 3 5.0 
Intermediate or post high school 
or diploma 
12 20.0 
High school 9 15.0 
Middle school 
9 15.0 
Primary school 9 15.0 
Illiterate 18 30.0 
Total 60 100.0 
SHT Graduate or postgraduate 3 5.0 
Intermediate or post high school 
or diploma 
6 10.0 
High school 15 25.0 
Middle school 3 5.0 
Primary school 18 30.0 
Illiterate 15 25.0 
Total 60 100.0 
COPD Graduate or postgraduate 6 10.0 
Intermediate or post high school 
or diploma 
5 8.3 
High school 12 20.0 
Middle school 12 20.0 
Primary school 10 16.7 
Illiterate 15 25.0 
Total 60 100.0 
 
Table.2 shows the Education of the participants 
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Occupation 
The following Figure 8 denotes the percentage of occupation of the 
study participants of the groups: DM, SHT and COPD. 25.6% (n=46) of the 
participants were skilled workers and unemployed each across the three 
categories. Clerical/shop owner or farmer constituted 19.4% of the total study 
sample. 
 
Figure 8: Occupation of the participants 
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Study groups Frequency Percent 
DM Clerical/shop owner or farmer 14 23.3 
Skilled worker 17 28.3 
Semiskilled worker 6 10.0 
Unskilled worker 9 15.0 
Unemployed 14 23.3 
Total 60 100.0 
SHT Clerical/shop owner or farmer 6 10.0 
Skilled worker 15 25.0 
Semiskilled worker 15 25.0 
Unskilled worker 12 20.0 
Unemployed 12 20.0 
Total 60 100.0 
COPD Clerical/shop owner or farmer 15 25.0 
Skilled worker 14 23.3 
Semiskilled worker 4 6.7 
Unskilled worker 7 11.7 
Unemployed 20 33.3 
Total 60 100.0 
 
Table 3: Occupation of the participants 
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Income 
The average income of the participants falls mainly within the salary 
range of Rs.13,874 – 18,497 (32.3%) and 9,249-13,875 (29.4%) with a small 
proportion of 7.8% within the salary range of 18,498-36,996.  No one is found 
in  the higher income group of Rs.>36,996.  Figure 9 shows the salary 
distribution of the study sample across DM, SHT and COPD.  
 
Figure 9: Salary distribution of the study sample 
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Salary range in rupees Frequency Percent 
DM 18,498  -36,996 6 10.0 
13,874 – 18,497 23 38.3 
9,249-13,875 17 28.3 
5,547- 9,248 6 10.0 
1,866- 5,546 8 13.3 
Total 60 100.0 
SHT 13,874 – 18,497 18 30.0 
9,249-13,875 24 40.0 
5,547- 9,248 9 15.0 
1,866- 5,546 9 15.0 
Total 60 100.0 
COPD 18,498  -36,996 8 13.3 
13,874 – 18,497 17 28.3 
9,249-13,875 12 20.0 
5,547- 9,248 17 28.3 
1,866- 5,546 6 10.0 
Total 60 100.0 
 
Table 4: Salary distribution of the study sample 
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Socio-economic Status 
The study population predominantly come from the lower 
socioeconomic status. The following figure 10 shows the distribution of the 
participants across various socio-economic groups.  
 
Figure 10 : Socioeconomic status of the study groups 
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DESCRIPTIVE STATISTICS 
Duration of illness 
Most of the participants (n=103) have duration of illness between  
5-10 years. Few participants (n=18) have duration of illness between 16-20 
years. Table 5 shows the duration of illness among the patients of DM, SHT 
and COPD. 
 
Figure 11: Duration of illness in years 
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Study groups Frequency Percent 
DM 5-10 36 60.0 
11-15 18 30.0 
16-20 6 10.0 
Total 60 100.0 
SHT 5-10 33 55.0 
11-15 18 30.0 
16-20 9 15.0 
Total 60 100.0 
COPD 5-10 34 56.7 
11-15 23 38.3 
16-20 3 5.0 
Total 60 100.0 
 
Table 5: Duration of illness in years 
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Presence of complications 
Figure 12 shows the presence and absence of complications in the 
various study samples. The presence of complications is more in COPD 
(51.7%), followed by DM (35%) and SHT (30%).  
 
Figure 12 : Presence of complications 
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Hospitalisations 
Figure .13 shows the number of hospitalisations in each group. More 
patients were hospitalised atleast once during their course of illness in COPD 
group (66.7%) followed by DM (56.6%) and SHT (33.4%). 
  
Figure 13: Number of hospitalizations for each group 
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The following table shows the number of hospitalizations per group 
during their course of illness. Most of the participants (n=86, 47.8%) were 
non-hospitalized for their illness. 
Study groups Frequency Percent 
DM 0 26 43.3 
1 17 28.3 
2 14 23.3 
3 3 5.0 
Total 60 100.0 
SHT 0 40 66.7 
1 15 25.0 
2 4 6.7 
3 1 1.7 
Total 60 100.0 
COPD 0 20 33.3 
1 21 35.0 
2 13 21.7 
3 6 10.0 
Total 60 100.0 
 
Table 6: Number of hospitalisations in each group 
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Adherence to medication 
Most of them (n=81, 45%) have a medium level of adherence to 
medication. Figure 14  depicts the level of adherence of medication by 
various study groups. 
 
Figure14: Adherence to medication 
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Prevalence of depression 
Figure 15 shows the prevalence of depression among the study 
participants with 80.6% (n=145) of the total study population being normal, 
and depression with 19.4 % as mild depression: 6.1% (n=11), moderate 
depression: 9.4% (n=17) and severe depression : 3.9% (n=7).  The prevalence 
of depressive symptoms is more among COPD group (28.4%) followed by 
DM (23.3%) and SHT (6.7%) 
 
Figure 15: Depression among the study participants 
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Prevalence of anxiety  
Figure 16 shows the prevalence of anxiety among the study 
participants with 81.1% (n=146) of the total study population being normal, 
mild to moderate: 8.3% (n=15), moderate to severe : 8.3% (n=15) and very 
severe anxiety 2.2% (n=4). 
 
Figure 16: Anxiety among the study participants 
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 HAMA Frequency Percent 
DM  Normal 47 78.3 
Mild to moderate 6 10.0 
Moderate to severe 4 6.7 
Very severe 3 5.0 
Total 60 100.0 
SHT Normal 53 88.3 
Mild to moderate 3 5.0 
Moderate to severe 4 6.7 
Total 60 100.0 
COPD  Normal 46 76.7 
Mild to moderate 6 10.0 
Moderate to severe 7 11.7 
Very severe 1 1.7 
Total 60 100.0 
 
Table 7: Anxiety among the study participants 
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INFERENTIAL STATISTICS 
Table 8: Relationship between gender and Depression 
 
BDI 
Total 
Chi-
Square 
test 
Normal Mild Moderate Severe 
Sex Male 72 6 14 1 93 P=0.014 
Female 73 5 3 6 87   
Total 145 11 17 7 180   
  
The above table shows that there is a statistically significant 
relationship between Gender and BDI shown by p<0.014. 
 
 
 
 
 
 
62 
 
Table 9 shows the relationship between depression and DM, SHT and 
COPD. 
Table 2: Statistical analysis of relationship between depression and 
chronic diseases 
 BDI Total 
Normal Mild Moderate Severe 
 DM 46 6 5 3 60 
SHT 56 1 2 1 60 
COPD 43 4 10 3 60 
Total 145 11 17 7 180 
 
Depressive symptoms are found more  in COPD group( n=17), 
followed by Diabetes ( n= 14) and hypertension has depressive symptoms in 
only 4 out of 60 subjects. 
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Table 10: Chi-square test for independence 
The following table documents the chi-square test for independence 
depression and DM, SHT, COPD. 
Chi-Square Tests 
 Value df P 
Pearson Chi-Square 12.279 6 .056 
N 180   
 
Chi-Square test for independence indicated no significant association 
between depression and DM, SHT, COPD with Χ2 (6, N=180) = 12.28, 
p=0.056. 
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Statistical test to compare depression among the three groups 
Table 11 shows the One-way ANOVA test .There is a statistically 
significant difference between our group means. The significance level is 
0.015 (p = .015), which is below 0.05. Therefore, there is a statistically 
significant difference in the mean BDI scores between the different groups of 
study.  
 Sum of 
Squares 
df Mean 
Square 
F Sig. 
Between 
Groups 
5.433 2 2.717 4.279 .015 
Within 
Groups 
112.367 177 .635 
Total 117.800 179  
 
Table 11: One-way ANOVA test to compare depression  
among three groups 
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Table 12 shows multiple comparisons, that shows SHT and COPD 
significantly differ in BDI scores with p=0.013. 
Table 5:Multiple Comparisons 
Dependent Variable:   BDI 
Tukey HSD 
(I) 
category 
(J) 
category 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
DM SHT .283 .145 .129 -.06 .63 
COPD -.133 .145 .631 -.48 .21 
SHT DM -.283 .145 .129 -.63 .06 
COPD -.417* .145 .013 -.76 -.07 
COPD DM .133 .145 .631 -.21 .48 
SHT .417* .145 .013 .07 .76 
*. The mean difference is significant at the 0.05 level. 
 
Table 12: Multiple comparisons of BDI scores with DM,SHT and COPD 
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Statistical test to compare anxiety among the three groups 
Table 13 shows the One-way ANOVA test .There is no statistically 
significant difference between our group means. The significance level is 
0.215 (p = .215), which is above 0.05. Therefore, there is no statistically 
significant difference in the mean anxiety scores between the different groups 
of study. 
 
Sum of 
Squares 
df 
Mean 
Square 
F Sig. 
Between 
Groups 
1.600 2 .800 1.550 .215 
Within 
Groups 
91.350 177 .516 
Total 92.950 179  
 
Table 13: One-way ANOVA test to compare anxiety among three groups 
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Table 14 shows multiple comparisons, no significant difference in HAMA 
scores between groups is noted 
Table 7 :Multiple Comparisons 
Dependent Variable:   HAM-A 
Tukey HSD 
(I) 
category 
(J) 
category 
Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
DM SHT .200 .131 .282 -.11 .51 
COPD .000 .131 1.000 -.31 .31 
SHT DM -.200 .131 .282 -.51 .11 
COPD -.200 .131 .282 -.51 .11 
COPD DM .000 .131 1.000 -.31 .31 
SHT .200 .131 .282 -.11 .51 
 
Table 14: multiple comparisons of HAMA scores  
with DM, SHT and COPD 
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Table 15 depicts the comparison of depression and duration of illness 
between the study groups 
 
Duration 
Total 5-10 11-15 16-20 
DM BDI Normal 31 15 0 46 
Mild 1 2 3 6 
Moderate 1 1 3 5 
Severe 3 0 0 3 
Total 34 36 18 6 
SHT BDI Normal 32 15 9 56 
Mild 0 1 0 1 
Moderate 0 2 0 2 
Severe 1 0 0 1 
Total 33 18 9 60 
COPD BDI Normal 29 14 0 43 
Mild 0 4 0 4 
Moderate 5 3 2 10 
Severe 0 2 1 3 
Total 34 23 3 60 
 
15 patients have depressive symptoms with duration of illness between 
11 – 15 years followed by 11 patients have depressive symptoms with 
duration of illness between 5 – 10 years and only 9 patients have depressive 
symptoms with duration of their illness between 16 -20 years. 
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Table. 16 illustrates comparison of depression and hospital stay between 
the study groups 
 
Duration of hospital stay 
Total 0 1 2 3 
DM BDI Normal 26 13 5 2 46 
Mild 0 2 3 1 6 
Moderate 0 2 3 0 5 
Severe 0 0 3 0 3 
Total 26 17 14 3 60 
SHT BDI Normal 37 14 4 1 56 
Mild 1 0 0 0 1 
Moderate 2 0 0 0 2 
Severe 0 1 0 0 1 
Total 40 15 4 1 60 
COPD BDI Normal 20 15 7 1 43 
Mild 0 3 0 1 4 
Moderate 0 1 6 3 10 
Severe 0 2 0 1 3 
Total 20 21 13 6 60 
 
            11 patients (n=11 ,N=180) having prior hospitalizations once  and 15 
patients (n=15, N=180) having prior hospitalizations twice have depressive 
symptoms. Only one patient with severe depression and COPD has had 3 
hospital stays. 3 patients without any hospital stays have depressive 
symptoms. 
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Table 17 shows the comparison of depression and adherence to 
medication between the study groups.  
 
Adherence 
Total low medium high 
DM BDI Normal 25 16 5 46 
Mild 1 4 1 6 
Moderate 1 4 0 5 
Severe 0 0 3 3 
Total 27 24 9 60 
SHT BDI Normal 28 25 3 56 
Mild 0 0 1 1 
Moderate 0 1 1 2 
Severe 0 1 0 1 
Total 28 27 5 60 
COPD BDI Normal 15 21 7 43 
Mild 0 4 0 4 
Moderate 0 3 7 10 
Severe 0 2 1 3 
Total 15 30 15 60 
 
Table 17: Comparison of depression and adherence to medication 
between the study groups. High adherence to medication is very low in SHT 
compared to the other groups under study. 
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Table 18: Comparison of depression and presence of complications 
between the study groups 
 
Complications 
Total Yes No 
 DM BDI Normal 11 35 46 
Mild 3 3 6 
Moderate 4 1 5 
Severe 3 0 3 
Total 21 39 60 
SHT BDI Normal 17 39 56 
Mild 0 1 1 
Moderate 0 2 2 
Severe 1 0 1 
Total 18 42 60 
COPD BDI Normal 14 29 43 
Mild 4 0 4 
Moderate 10 0 10 
Severe 3 0 3 
Total 31 29 60 
 
Out of 70 patients(n=70, N=180)having complications due to their 
illnesses, 10  patients from DM, one from SHT and 17 patients from COPD 
have depressive symptoms. Out of 110 patients having no complications,    
7 patients have depressive symptoms . 
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Table 19 depicts the comparison of anxiety and duration of illness 
between the study groups. 
 
Duration 
Total 5-10 11-15 16-20 
DM  HAM-A Normal 32 9 6 47 
Mild to 
moderate 
3 3 0 6 
Moderate to 
severe 
1 3 0 4 
Very severe 0 3 0 3 
Total 36 18 6 60 
SHT HAM-A Normal 32 15 6 53 
Mild to 
moderate 
0 1 2 3 
Moderate to 
severe 
1 2 1 4 
Total 33 18 9 60 
COPD HAM-A Normal 28 15 3 46 
Mild to 
moderate 
3 3 0 6 
Moderate to 
severe 
3 4 0 7 
Very severe 0 1 0 1 
Total 34 23 3 60 
 
3 patients from SHT group having more than 15 years of their duration 
of illness have anxiety symptoms.   
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Table 20 depicts the comparison of anxiety and presence of complications 
between the study groups 
 
Complications 
Total Yes No 
DM HAM-A Normal 10 37 47 
Mild to 
moderate 
4 2 6 
Moderate 
to severe 
4 0 4 
Very severe 3 0 3 
Total 21 39 60 
SHT 
 
HAM-A 
 
Normal 11 42 53 
Mild to 
moderate 
3 0 3 
Moderate 
to severe 
4 0 4 
Total 18 42 60 
COPD HAM-A Normal 17 29 46 
 Mild to 
moderate 
6 0 6 
Moderate 
to severe 
7 0 7 
Very severe 1 0 1 
Total 31 29 60 
 
Out of 70 patients (n=70 , N=180 ) having complications, 32 patients 
have anxiety symptoms and out of 110 patients having no complications,  
2 patients from DM group have anxiety symptoms. 
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Table 21 depicts the comparison of anxiety and Number of hospital stay 
between the study groups 
 
Number of hospital stay 
Total 0 1 2 3 
DM HAM-
A 
Normal 25 14 7 1 47 
Mild to 
moderate 
1 3 2 0 6 
Moderate 
to severe 
0 0 3 1 4 
Very 
severe 
0 0 2 1 3 
Total 26 17 14 3 60 
SHT HAM-
A 
Normal 40 10 3 0 53 
Mild to 
moderate 
0 2 1 0 3 
Moderate 
to severe 
0 3 0 1 4 
Total 40 15 4 1 60 
COPD HAM-
A 
Normal 20 15 6 5 46 
Mild to 
moderate 
0 6 0 0 6 
Moderate 
to severe 
0 0 6 1 7 
Very 
severe 
0 0 1 0 1 
Total 20 21 13 6 60 
 
14  patients having prior hospitalizations once , 15 patients having 
prior hospitalizations twice and 4 having thrice have anxiety.  
75 
 
Table 22 depicts the comparison of anxiety and adherence to medication 
between the study groups 
 
Adherence 
Total Low Medium High 
DM HAM-A Normal 27 20 0 47 
Mild to 
moderate 
0 1 5 6 
Moderate 
to severe 
0 3 1 4 
Very 
severe 
0 0 3 3 
Total 27 24 9 60 
SHT HAM-A Normal 28 23 2 53 
Mild to 
moderate 
0 1 2 3 
Moderate 
to severe 
0 3 1 4 
Total 28 27 5 60 
COPD HAM-A Normal 15 19 12 46 
 Mild to 
moderate 
0 6 0 6 
Moderate 
to severe 
0 4 3 7 
Very 
severe 
0 1 0 1 
Total 15 30 15 60 
 
Only 29 patients (n=29, N=180) from study group have high adherence 
to their medication. 
 DISCUSSION 
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DISCUSSION 
         The current study on the patients of chronic illnesses like diabetes 
mellitus, systemic hypertension and chronic obstructive lung disease to 
estimate the prevalence of Depression and Anxiety in Type 2 Diabetes 
Mellitus, Systemic Hypertension and Chronic Obstructive Lung Disease and 
to compare the patients of DM, SHT and COPD on depression and anxiety 
throws light on few significant facts.  
         In our study the prevalence of depressive symptoms among diabetic 
population is 23.3% with 21 males of the study showing depression against 14 
females. The chi-square test shows a significant association with p<0.14.  
This study substantiates with the finding of Poongothai S et al, and her 
colleagues at 2009; found that, the overall prevalence of depression was 
15.1%, among this, the prevalence of depression was higher in females 
(16.3%) than in males (13.9%). 
         Prevalence  of depression among DM is widely studied  and Table 9  
and Figure 15 show the prevalence of depression among the DM is n=14 with 
5% of the DM cases reporting severe depression. This correlates with the 
study of Biglanet al, Connell36 et al, Geringer37 et al, Marcus38et al, and 
Nalibott39 et al that reported a higher prevalence of depression in DM.   
Previous studies show that depression in diabetes is persistent and/or 
recurrent. In longitudinal and follow up studies, the rates of depression 
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persistence or recurrence have been reported to range widely, between 11.6 % 
and 92 %, depending on sample sizes, depression diagnostic criteria and 
depression classification. Since our study is a cross sectional study, our 
frontiers of exploration on the persistence of these symptoms is minimal. 
         This relationship between depression and DM is established in our study 
but the direction of relationship could not be explained due to the smaller 
sample size and limited focus of the study.  Another lines of research that 
could not be exploited are the absence of controls. Further is DM the sole 
factor responsible for depression or is it a mediator or moderator is another 
area that could not be assessed in this study. 
         The current study also posits a possible relationship between DM and 
anxiety with 13 cases showing varying degrees of anxiety. Table 7 shows that 
21.7% of  DM group had anxiety and out of them 5% of the cases had severe 
anxiety. A multivariate analysis of a similar type of study at Malaysia, 
Kurubaran Ganasegeranet al, 2014, demonstrated the factors connected with 
depression and anxiety among type 2 diabetic patients: the age of onset, 
ethnicity, monthly income and the complications associated with diabetes 
were significantly influenced the causation of both depression and anxiety 
among the type 2 diabetic patients. 
         Our study shows a higher prevalence of depression with 17 of the 60 
participants with COPD showing varing degrees of depression with 3 of them 
manifesting severe depression. Previous studies on prevalence of depression 
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in patients with chronic obstructive lung disease showed a varied prevalence 
(7 to 42%). Another study of literature showed a similar claim (van Ede, L, 
Yzermans, CJ, Brouwer, HJ).  
        The prevalence of anxiety in COPD patients (23.4%) is higher among all 
the three groups, shown in Fig. 16 and this finding is in tandem with similar 
studies : Gehan et al found 22.5% patients of COPD had anxiety, Yellowlees 
found That 34 % had anxiety disorder.  
         The prevalence of anxiety among DM is also high as shown in the study 
which is in support of  Barkeret al, 2008 and Grisbyet al, 2001 who showed a 
similar result. Harmanns et al, 2005, found that, 19.3% of the diabetic patients 
had anxiety symptoms and 5.9% of them were fulfilling the criteria of anxiety 
disorders. The current study had all patients fulfilling the criteria. 
         The existing literature on the relationship of anxiety and depression to 
systemic hypertension is minimal. The present study shows the prevalence of 
depression to be 6.7% and anxiety to be 11.7%. Grimsrud A, Myer L, Seedat 
S, Williams D, Stein DJ showed that 8.1% have anxiety and 4.9% have 
depression The prevalence of depression and anxiety found in our study is 
significantly higher than the previous study. This can be attributed to the 
sampling at the tertiary care center, which usually reports higher prevalence. 
Further this is lower than another review study of Huapaya, L et al  who 
reported 37% of depression in SHT. 
 CONCLUSION 
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CONCLUSION 
  This cross sectional study yielded significant results that could be 
compared with the previous studies. Since this is a cross sectional study, 
methodologically the research is limited. This research throws light on the 
prevalence of anxiety and depression in DM, SHT and COPD suggesting 
other avenues of research in multiple angles of thinking. 
         The inferences from this study can be summarized that there is an 
increased prevalence of anxiety and depression in patients with DM, SHT and 
COPD. But owing to the small sample size and limited focus of the study, it 
cannot establish how far there is a coexistent chronic illnesses and how far 
they independently and collectively contribute to the psychiatric illnesses. 
Maybe two chronic illnesses compound the effect on depression and anxiety. 
         Further the direction of the relationship between these variables could 
also not be established. The generalizability of the study is also limited due to 
smaller sample size and the recruitment of the samples from a single urban 
setting. 
          Considering the epidemic nature of these chronic illnesses and 
depression, the problem of these issues are multiple and complex. It is 
essential to note that the association between these conditions and anxiety-
depression is multifaceted and the harmful effects of both are compounded in 
case of co morbidity. Further the current study do not take into account the co 
occurrence of two or more chronic illness in patients suffering from anxiety 
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disorder or depression or both. Community studies show significant increased 
risks of prevalent and incident depression.  Psychosomatic hypotheses are 
supported by the above finding.  
          Another important consideration is the increased incidence of diabetes 
in patients with depression called persistent treatment resistant depression. 
Our existing literatures do not provide knowledge on all these. Therefore it is 
mandatory for us to explore these areas of co morbidity in light of these 
chronic illnesses causing anxiety and depression. 
          Further studies that needs to be done are; longitudinal study to 
understand the relationship, duration and course of these chronic illnesses in 
the light of anxiety and depression. Secondly, it is interesting to study how 
anxiety disorders lead to these chronic illnesses and also how diabetes proves 
to be the prime etiology in these diseases. Even intriguing is the presence of 
anxiety and depression in a person and how these two affect the 
etiopathogenesis of these chronic illnesses, course, duration outcome and 
treatment.  
          The potential implications from this study would help us to formulate 
treatment protocols and concentrate on the comprehensive care. Our idea of 
treatment of these diseases in the presence of depression and anxiety would be 
drastically influenced. This leaves room for the future researchers to explore 
these areas of association between psychiatric disorders, chronic illnesses, 
comorbidity, treatment and other factors that has a telling impact on 
comprehensive care and treatment.  
 LIMITATIONS 
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LIMITATIONS OF THE STUDY 
1.  Only a small number of samples (60 patients from each group)  
participated in this study. 
 2.  The study was done at a single point of time, which prevents episodic 
nature of depression and anxiety symptom  evaluation . 
3.  Being a cross sectional study, it was difficult to ascertain whether 
depression or anxiety which was identified in the groups was cause or 
effect of the chronic illnesses. 
4.  This study was conducted in a tertiary care hospital where most of the 
patients had severe symptoms and hence the findings of this study 
cannot be generalized. 
5.  Since this study was done in a single site, the generalisability of the 
results are limited. 
6.  The presence of the study among the urban population limits our 
understanding of the prevalence of depression and anxiety in DM, SHT 
and COPD among rural population. 
  
 RECOMMENDATIONS 
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RECOMMENDATIONS 
         More studies are required to find out the strength of the relationship 
between DM, SHT and COPD to depression and anxiety, their independent 
association to each other and to the chronic illness. 
         Future studies should concentrate more on sampling a larger population 
and develop a new methodological approach to assess the exact prevalence.  
         Longitudinal studies to find out the course of the illness and their 
relationship with anxiety and depression should be considered.  
         An exploratory study to understand various mediators and moderators of 
anxiety and depression in DM, SHT and COPD should be considered. 
 ANNEXURES 
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 நீரிழிவு நநோய், உயர் இரத்த அழுத்தம் மற்றும் நோள்பட்ட 
நுரரயீரல் அரடப்பு நநோய் நபோன்ற மருத்துவ நநோய்களில் 
மன அழுத்தம் மற்றும் பதட்ட நநோய் நபோன்ற மன 
நநோய்களின் ஒரு மதிப்பீட்டு ஆய்வு. 
தகவல்: 
ஆரோய்ச்சியின் நநோக்கமும், பயன்களும்: 
உங்கள் பங்ககற்பு திட்டமிடப்பட்டுள்ள இந்த மருத்துவ ஆராய்ச்சி ஆய்வின் 
க ாக்கம்: 
மன அழுத்தம் மற்றும் பதட்ட க ாய் இதர மருத்துவ க ாய்களில் 
பபாதுவாக காணப்படுகிறது. இந்த மன க ாய்கள்  மக்கு உடல்  ல குறறபாட்றட 
உண்டு பண்ணுவகதாடல்லாமல்  மது மருத்துவ பசலவினங்கறளயும் 
அதிகப்படுத்துகிறது. பதட்ட க ாய் அதிகப்படியான உளவியல் எதிர்விறனகறள 
 ீரிழிவு க ாயாளிகளுக்கு ஏற்படுத்துகிறது. பதட்ட க ாய்,  ீரிழிவு க ாயாளிகளின் 
க ாயின் தன்றமறய அதிகப்படுத்தி சமூக மற்றும் பதாழில்சார் சூழலில் 
அவர்களது தனிப்பட்ட பங்கிறன பழுதாக்குகிறது. . உயர் இரத்த அழுத்தம் மற்றும் 
 ாள்பட்ட நுறரயரீல் அறடப்பு க ாய் க ாய்கறள மன அழுத்தம் மற்றும் பதட்ட 
க ாய் கமலும் கமாசமாக்குகிறது. மன அழுத்தம் மற்றும் பதட்ட க ாய் கபான்ற 
மனக ாய்கள்  ீரிழிவு க ாய், உயர் இரத்த அழுத்தம் மற்றும்  ாள்பட்ட நுறரயரீல் 
அறடப்பு க ாய் கபான்ற மருத்துவ க ாய்களில் அதிகரித்து வரும் இனறறய 
சூழலில் அந்த க ாய்கறள மதிப்படீு பசய்வது அவசியமாகிறது. இதுகவ  ம் 
ஆய்வின் க ாக்கம். அவ்வாறு மதிப்படீு பசய்தவதன் மூலம் இதர மருத்துவ 
க ாய்ககளாடு இந்த மன க ாய்களுக்கும் தகுந்த மருத்துவம் பசய்து 
க ாயாளிகளின் வாழ்க்றக தரத்றத உயர்த்தலாம். 
 ஆய்வு நரடமுரறகள்: 
 ீரிழிவு க ாய் அல்லது உயர் இரத்த அழுத்தம் அல்லது  ாள்பட்ட 
நுறரயரீல் அறடப்பு க ாய் கபான்ற மருத்துவ க ாய்களுக்காக அந்தந்த சிறப்பு 
மருத்துவ பிரிவில் சிகிச்றச பபற்று வரும், 30 முதல் 50 வயதுறடயவர்களும், 
இன்ன பிற மன க ாய் மற்றும் கபாறதப்பழக்கம் இல்லாதவர்களும் இந்த 
ஆய்வுக்கு தகுதியானவர்கள். 
அந்தரங்கத் தன்ரம: 
உங்கள் மருத்துவப் பதிகவடுகள் மிகவும் அந்தரங்கமாக றவத்துக் 
பகாள்ளப்படும் மற்றும் இன்ன பிற மருத்துவர்கள்/விஞ்ஞானிகள்/இந்த ஆய்வின் 
தணிக்றகயாளர்கள் அல்லது ஆராய்ச்சி ஆதரவாளர்களின் பிரதி ிதிகள் 
ஆகிகயாரிடமும் அறவ பவளிப்படுத்தப்படும். இந்த ஆய்வின் முடிவுகள் 
அறிவியல் பத்திரிக்றககளில் பிரசுரிக்கப்படலாம். ஆனால் பபயறர 
பவளியிடுவதன்மூலம் க ாயாளிகள் அறடயாளம் காட்டப்பட மாட்டார்கள். 
ஆய்வில் உங்கள் பங்நகற்பு மற்றும் உங்கள் உரிரமகள்: 
இந்த ஆய்வில் உங்கள் பங்ககற்பு முழுவதும் உங்களுறடய விருப்பத்றதச் 
சார்ந்தது. இதில்  ீங்கள் பங்ககற்க மறுக்ககவா, பாதியில் பவளிகயறி விடகவா 
அல்லது குறிப்பிட்ட ககள்விகளுக்கு விறடயளிக்க மறுக்ககவா, உங்களுக்கு முழு 
உரிறம உண்டு. எப்படி இருந்தாலும் உங்கள் உடல் ிறலக்ககற்ப, உங்களுக்கு 
பபாருத்தமான சிகிச்றச பதாடர்ந்து அளிக்கப்படும். தாங்கள் இது குறித்து கவறு 
விபரங்கள் பதரிந்து பகாள்ள விரும்பினால், எங்களிடம் ககட்டுத் 
பதரிந்துபகாள்ளலாம். 
கமலும் விபரங்கள் அறிய கீழ் கண்ட  பறர அணுகவும்: 
 
(தனியாகப் பிரித்பதடுத்து, ஆய்வில் பங்ககற்பவரிடம் தரப்பட கவண்டும்) 
 PROFORMA 
SOCIO DEMOGRAPHIC FACTORS   
     Name:  
1.   Age 
2.   Sex                      1.  Male       2.  Female 
3.    Religion            1. Hinduism    2. Christianity   3.  Islam     4.  Others 
4.    Family distribution     1.  Nuclear    2.  Joint family 
5.    Residence     1.  Urban   2.  Rural 
6.    Marital status    1.  Married   2.  Unmarried 
7.     Education     1.   Profession   2.   Graduate or post graduate   
3.  Intermediate or post high school or diploma    
4.    High school       5.     Middle school                                 
6.     Primary school  7.     Illiterate 
8. Occupation         1.    Profession  2.    semi Profession  3.  Clerical/shop  
owner or farmer    4.     Skilled worker   5.   Semi skilled 
worker    6.    Unskilled worker  7.   Unemployed 
9. Income                 1. Rs.  >36,997    2.   Rs. 18,498  -36,996     
3.   Rs. 13,874 – 18,497  4.  Rs.  9,249-13,875     
5.   Rs.5,547- 9,248    6.  Rs. 1,866- 5,546                                  
7. Rs.  <1,865 
10.  Socioeconomic status   1.   Upper   2.   Upper middle  3.   Middle/ lower  
    middle    4.  Lower/ upper  lower    5.  Lower 
Clinical factors 
11.   Duration of illness   1.   5 – 10 yrs   2.  11 – 15 yrs   3.   16- 20 yrs                                         
    4.   > 20  yrs 
 12. Complication         1. Yes     2. No 
13.Hospital stays   
14. Medication adherence    1.  High adherence   ( 0 )  2. Medium   
     adherence (1 -2)  3. Low adherence  (3-8) 
15.BDI         1. Normal  ( 0 -9)   2. mild  (10-16 )    
3. moderate  (17-29)  4. Severe  (30-63) 
16. HAMA      1.  normal  (<17)   2.  Mild to moderate  
(18-24 ) 3.  Moderate  to  severe (25-30)     
4.  Very severe  ( >30). 
 
   
  
  
  
 BDI TAMIL VERSION 
A. 0 |õß PÁø»²hß C¸UPÂÀø». 
 1. |õß PÁø»²hß C¸UQ@Óß. 
 2. |õß G¨@£õx® PÁø»²hß C¸UQ@Óß. Av¼¸¢x «Í 
•i¯ÂÀø». 
 3. |õß PÁø»²hß C¸¨£øu GßÚõÀ uõ[QU öPõÒÍ 
•i¯ÂÀø». 
B. 0 Á¸[Põ»zøu¨ £ØÔ |À»£i¯õP C¸UPö©Ú 
{øÚUQ@Óß. 
 1a. Gvº Põ»zøu¨ £ØÔ ªPÄ® PÁø»¯õP C¸UQ@Óß. 
 2. |õß G¨@£õx® PÁø»²hß C¸UQ@Óß. Av¼¸¢x «Í 
•i¯ÂÀø». 
 3. |õß PÁø»²hß C¸¨£øu GßÚõÀ uõ[QU öPõÒÍ 
•i¯ÂÀø».  
C. 0 |õß @uõÀÂ¯øh¢uuõP EnµÂÀø» 
 1. |õß J¸ Œõuõµn©õÚ ©ÛuøÚ Âh AvP©õP 
@uõÀÂ¯øh¢xÒ@Íß.  
 2a. |ßø©¯õÚøÁ GÚUS KµÍ@Á QøhzxÒÍx. 
 3. |õß •ØÔ¾® @uõÀÂ¯øh¢u ©ÛuÚõP {øÚUQ@Óß 
(ö£Ø@Óõº, PnÁß, ©øÚÂ GßÓ •øÓ°À) 
D. 0 |õß SÔ¨¤hz uS¢u •øÓ°À v¸¨v¯ØÓÁÚõP CÀø» 
 1a. ö£¸®£õ¾® GÀ»õ @|µ[PÎ¾® GÚUS A¾¨¦ 
umi²ÒÍx. 
 1b. CuØS •ß¦ GÆÁõÖ Œ¢@uõå©õÚ AÝ£ÂzxU 
öPõsi¸¢@u@Úõ Ax ©õv› C¨@£õx 
C¸UP•i¯ÂÀø».  
 2. G¢u J¸ ö£õ¸Î@»õ, {PÌa]°@»õ |õß v¸¨v¯øh¯ 
•i¯ÂÀø». 
 3. GÀ»õÁØÔ¾® v¸¨v CÀ»õuÁÚõP C¸UQ@Óß.  
E. 0 |õß E£@¯õPªÀ»õuÁÚõP EnµÂÀø» 
 1. Ö£¸®£õ»õÚ @|µ® |õß @©õ®, EuÁõUPøµ GßÖ 
EnºQ@Óß. 
 2a. |õß ªPÄ® SØÓ EnºÄhÛ¸UQ@Óß. 
 2b. GÀ»õ @|µzv»® ¯õ¸US®  E£@¯õPªÀ»õu ©ÛuÚõP  
EnºQ@Óß. 
 3. |õß ªPÄ® öPmhÁÚõP@Áõ AÀ»x GuØS® 
E£@¯õPªÀ»õuÁÚõP@Áõ EnºQ@Óß.  
 F. 0 |õß usiUP¨£kÁuõP {øÚUPÂÀø». 
 1. H@uÝ® öPkxÀ öŒ#²®£i GÚUS HØ£hUTk® GßÖ 
EnºQ@Óß. 
 2. GÚUS {aŒ¯® ushøÚ QøhUS® 
 3a. |õß ushøÚ ö£Óz uSv²øh¯ÁõP {øÚUQ@Óß. 
 3b. GÚUS ushøÚ QøhUP Â¸®¦Q@Óß.  
G. 0 GßÛhzuvÀ GÚUS H©õØÓªÀø» 
 1a. |õß H©õØÓøh¢v¸UQ@Óß. 
 1b. |õß GßøÚ@¯ Â¸®£ÂÀø» 
 2. |õß GßøÚ@¯ öÁÖUQ@Óß. 
 2b. |õß GßøÚ¨ £ØÔ@¯ {øÚUQ@Óß 
H. 0 ©ØÓ GÁøµ²® Âh |õß @©õŒ©õÚÁß GßÖ 
{øÚUPÂÀø». 
 1a. |õß GßÝøh¯ uÁÖPÐUPõP GßøÚ@¯ Pkø©¯õP 
Â©ºa]zxU öPõÒ£Áß 
 2b. uÁÓõP |hUS® GÀ»õ Põ›¯[PÐUS® |õ@Ú Põµn® GÚ 
{øÚUQ@Óß.  
I. 0 GßøÚ |õ@Ú xß¦ÖzvU öPõÒÍ {øÚUPÂÀø» 
 1. GßøÚ |õ@Ú xß¦ÖzvU öPõÒÍ {øÚUQ@Óß. BÚõÀ 
Aøu {øÓ@ÁØÔU öPõÒÍ•i¯ÂÀø». 
 2. |õß uØöPõø» öŒ#x öPõÒÍ @Ási¯ vmh[PÐhß 
C¸UQ@Óß. 
 2a. |õß GßøÚ@¯ öÁÖUQ@Óß. 
 3. GßÚõÀ •i²©õÚõÀ GßøÚ |õ@Ú öPõø» öŒ#x 
öPõÒ@Áß. 
J 0 Œõuõµn©õP |õß AÊÁx Qøh¯õx 
 1. CuØS •ß¦ EÒÍøu Âh C¨@£õx AvP® AÊQ@Óß. 
 2. C¨@£õx GÀ»õ @|µ[PÎ¾® AÊQ@Óß. GßÚõÀ {Özu 
•i¯ÂÀø». 
 3. C¨@£õöuÀ»õ® |õß AÇ@Áskö©ßÖ Â¸®¤ÚõÀ Th 
AÇ•i¯ÂÀø».  
K 0 C¨@£õx |õß CuØS •ß¦ EÒÍøu Âh G›aŒÀ £kÁx 
Qøh¯õx. 
 1. C¨@£õöuÀ»õ® GÚUS GÎuõP G›aŒÀ HØ£mk ÂkQÓx. 
 2. GÀ»õ  @ÁøÍPÎ¾® GÚUS G›aŒÀ EshõQÓx. 
 3 GÚUS G›aŒÀ ‰mhU Ti¯ Põ›¯[PÒ |h¢uõÀ Th 
C¨@£õx GÚUS G›aŒÀ HØ£hõ©À @£õ#ÂkQÓx. 
 L 0 ©ØÓÁºPÎh® GÚUS EÒÍ Dk£õk JßÖ® 
SøÓ¯ÂÀø». 
 1. CuØS •ß¦ C¸¢u©õv› ©ØÓÁºPÎß @©À GÚUS EÒÍ 
Dk£õk ]Ôx SøÓ¢u Põn¨£kQÓx. 
 2. ©ØÓÁºPÎß @©À EÒÍ GÚx Â¸¨£® ö£¸®£õ¾® 
SøÓ¢xÒÍx. 
 3. ©ØÓÁºPÎß @©À EÒÍ GÚx Â¸¨£® •ÊÁx©õPU 
SøÓ¢x AÁºPøÍ¨ £ØÔ¯ AUPøÓ Hx® GÚUS 
Qøh¯õx. 
M 0 G¨@£õx® @£õÀ J¸ Põ›¯zøu¨ £ØÔ  |À»£i¯õPz 
wº©õÛUP •iQÓx.  
 1. HuõÁx Põ›¯[PÎÀ •iÄ Gk¨£øu |õß {Özv øÁzxU 
öPõÒQ@Óß. HöÚÛÀ Gß «@u GÚUS  |®¤UøP CÀø».  
 2. ©ØÓÁºPÒ EuÂ CÀ»õ©À G¢u J¸ Põ›¯zøu wº©õÛUP 
•i¯ÂÀø».  
 3. C¨@£õx G¢uU Põ›¯zøu¨ £ØÔ²® •iÄ GkUP@Á 
•i¯ÂÀø».  
N 0 CuØS  •ß¦ C¸¢uøu Âh¨ £õº¨£uØS |õß @©õŒ©õP 
CÀø».  
 1. |õß Á¯uõÚÁøµ¨ @£õßÖ Põm]¯Î¨£uõP@Áõ, AÀ»x 
PÁºa]¯ØÖ Põn¨£kÁuõP@Áõ {øÚzx ªPÄ® 
PÁø»¯øh¢xÒ@Íß.  
 2. GßÝøh¯ EhÀ @uõØÓzvÀ {µ¢uµ©õÚ ©õØÓ[PÒ 
HØ£mk |õß £õº¨£uØS PÁºa]¯ØÓÁÚõPU 
Põn¨£kÁuõP EnºQ@Óß.  
 3. |õß AÁ»mŒn©õP @uõØÓ©Î¨£uõP EnºQ@Óß.  
O 0 •ß¦ Põ›¯[PøÍa öŒ#¯ •i¢u ©õv›@¯ C¨@£õx 
öŒ#Q@Óß.  
 1a. HuõÁx  @Áø» öŒ#¯ Bµ®¤UP AvP¨£i¯õÚ •¯Ø] 
@uøÁ¨£kQÓx. 
 1b. •ß¦ @Áø» öŒ#ux @£õßÖ C¨@£õx @Áø» öŒ#¯ 
•iÁvÀø».  
 2. HuõÁx J¸ @Áø»ø¯a öŒ#¯ GßøÚ ªPÄ® Á¸zvU 
öPõÒÍ @Ási²ÒÍx. 
 3. G¢u @Áø»²® GßÚõÀ öŒ#¯ •iÁvÀø».  
P 0 G¨@£õx® @£õÀ GßÚõÀ |ßÓõP yUP •iQÓx. 
 1. CuØS •ß¦ EÒÍøu Âh C¨@£õx Põø»°À 
GÊ¢v¸US® @£õx ªPÄ® PøÍ¨£õP EÒÍx. 
 2. ÁÇUPzvØS ©õÓõP JßÖ AÀ»x Cµsk ©o @|µ® 
•ß£õP £kUøP°¼¸¢x ÂÈzxU öPõÒQ@Óß. ¤ÓS 
¡[P •iÁvÀø».  
 3. JÆöÁõ¸ |õÐ® Põø»°À ^UQµ® GÊ¢x ÂkQ@Óß. 
I¢x ©o @|µzvØS @©À yUP •iÁvÀø».  
 Q 0 Œõuõµn©õÚx AÀ»õ©À AvP©õP GÚUS  PøÍ¨¦ Gß£x 
HØ£kÁvÀø».  
 1. ÁÇUPzvØS ©õÓõP GÚUS C¨@£õx AvP©õÚ PøÍ¨¦ 
HØ£kQÓx.  
 2. G¢u J¸ Põ›¯•® öŒ#²® @£õx GÚUS  PøÍ¨¦ 
HØ£kQÓx. 
 3. G¢u J¸ Põ›¯•® öŒ#ÁuØS ªS¢u PøÍ¨¦ HØ£kQÓx.  
R 0 GÚUS  ÁÇUP® @£õ»@Á £] Gk¨£x @©õŒ©õP CÀø».  
 1. Œõuõµn©õP C¸¨£x @£õÀ GÚUS £] Gk¨£x AÆÁÍÄ 
|ßÓõP CÀø».  
 2. C¨@£x GÚUS £] Gk¨£x ªPÄ® @©õŒ©õP EÒÍx. 
 3. GÚUS G¨@£õx® £]@¯ Gk¨£vÀø». 
S 0 Œ«£ Põ»zvÀ GßÝøh¯ EhÀ Gøh°À SøÓÄ 
HØ£mhvÀø».  
 1. GßÝøh¯ Gøh°À 5 £ÄskUS @©À SøÓ¢xÒÍx.  
 2. GßÝøh¯ Gøh°À 10 £ÄskPÒ @©À SøÓ¢xÒÍx.  
 3. GßÝIh¯ Gøh°À 15 |ÄskUS @©À SøÓ¢xÒÍx.  
T 0 ÁÇUPzvØS ©õÓõP  |õß GßÝIh¯ EhÀ |»øÚ¨ £ØÔ 
AUPøÓ öPõshvÀø».  
 1. Eh®¤À HØ£k£ÁÚ @£õßÓ E£õøuPÐUPõP AÀ»x 
Á°ØÔÀ HØ£k® @PõÍõÖ AÀ»x ©»a]PÀ AÀ»x 
©ØÖ•ÒÍ Eh¼À  HØ£k®  Â¸¨£zuPõu 
EnºÄPÐUPõP GßÖ PÁø»¨£mi¸UQ@Óß.  
 2. |õß GÆÁõÖ EnºQ@Óß AÀ»x GøÚ¨£ØÔ EnºQ@Óß 
Gß£øu {øÚUP PiÚ©õP EÒÍøu¨ £ØÔ²® AUPøÓ 
öPõskÒ@Íß.  
 3. |õß G¨£i EnºQ@Óß Gß£v@»@¯ •ÊÁx©õP FßÔ 
ÂkQ@Óß.  
U 0 £õÀ EÓÄ Œ®£¢u©õP EØÍ BºÁzvÀ GßÛhzvÀ 
Œ«£zvÀ ©õØÓ®  Hx® HØ£mhuõP GÚUS öu›¯ÂÀø» 
 1. CuØS •ß¦ C¸¢uøu Âh C¨@£õx GÚUS £õÀ EÓÄ 
Œ®£¢u©õP ]Ôx BºÁ® SøÓ¢xÒÍx.  
 2. C¨@£õx GÚUS £õÀ EÓÄ Œ®£¢u©õÚÁØÔÀ BºÁ® 
ªPÄ® SøÓÁõP EÒÍx.  
 3. GÚUS £õÀ EÓÄ Œ®£¢u©õÚÁØÔÀ •ØÔ¾® BºÁ® 
SøÓ¢xÒÍx.  
 
 
  
 
  
  
 
  
 MORISKY MEDICATION ADHERENCE  
SCALE: MMAS – 8 
1. Do you feel sometimes forget to take your pills 
2. People sometimes miss taking their medications foe reasons other than 
forgetting. Thinking over the past two weeks, were there any days 
when you did not take your medicine ? 
3. Have you ever cut back or stopped taking your medicine telling your 
doctor because you felt worse when you took it ? 
4. When you travel or leave home, do you sometimes forget to bring 
along your medicine ? 
5. Did you take all your medicine yesterday ? 
6. When you feel like your symptoms are under control, do you 
sometimes stop taking your medicine ? 
7. Taking medicine every day is a real inconvenience for some people. 
Do you ever feel hassled about sticking to your treatment plan ? 
8. How often do you have difficulty remembering to take all your 
medicine ? 
A. Never / rarely 
B. Once in a while 
C. Sometimes 
D. Usually 
E. All the time 
Adherence MMAS-8 Score 
High adherence 0 
Medium adherence 1 – 2 
Low adherence 3 – 8 
 
 KEY TO MASTER CHART 
1.   Age 
2.   Sex                     1.    Male 
                                 2.    Female 
3.    Religion           1.    Hinduism   
                                2.     Christianity  
                                3.     Islam    
                                4.     Others 
4.   Family distribution  
                                1.   Nuclear  
                                2.   Joint family 
5.    Residence  
                                1.    Urban  
                                2.     Rural 
6.    Marital status   
                               1.   Married 
                               2.   Unmarried 
7.     Education   
                                 1.   Profession  or honours 
                                 2.   Graduate or post graduate  
                                 3.   Intermediate or post high school or diploma 
                                 4.    High school  
                                5.     Middle school  
                                 6.     Primary school   
                                7.     Illiterate 
8. Occupation         1.    Profession  
                          2.    semi Profession  
                          3.     Clerical/shop owner or farmer  
                          4.     Skilled worker   
                          5.    Semi skilled worker   
                          6.    Unskilled worker   
                                7.   Unemployed 
9. Income                1.   >36,997  
     (In rupees)          2.   18,498  -36,996   
                                3.   13,874 – 18,497   
                                4.   9,249-13,875    
                                5.   5,547- 9,248    
                                6.   1,866- 5,546    
                                7.   <1,865 
10.  Socioeconomic status    
                                 1.   Upper 
                                 2.   Upper middle   
                                 3.   Middle/ lower middle   
                                 4.  Lower/ upper  lower   
                                 5.  Lower 
 
 
 11.   Duration of illness   
                                      1.   5 – 10 years   
                                      2.  11 – 15 years   
                                      3.   16- 20 years   
                                      4.   > 20 years 
12. Complication           1. Yes  
                                       2. No 
13.Hospital stays 
14.Medication adherence    
                                      1.  High adherence     (score 0) 
                                      2. Medium  adherence   (score 1-2) 
                                      3.  Low adherence  (score 3-8) 
15.BDI   
                                     1. normal   ( score 0 -9) 
                                     2. mild   ( score 10 - 16) 
                                     3. moderate  ( score 17 - 29) 
                                     4. Severe  ( score 30 -63 ) 
16. HAM-A     
                                      1.  normal    ( score <17) 
                                      2.  Mild to moderate  ( score 18 - 24) 
                                      3.  Moderate  to  severe   ( score 25 - 30)  
     4.  Very severe  ( score >30 ) 
 
 
Age Sex Religion Family Residence Marital st Education Occupation Income SES Duration Complications Hosp.stay Adherence BDI HAM-A
42 2 1 1 1 1 5 7 3 4 1 2 1 2 1 1
45 2 2 2 1 1 7 6 4 4 1 1 2 3 4 2
50 1 1 1 2 1 7 5 3 4 2 1 3 2 1 3
38 2 3 1 1 1 5 4 5 4 1 2 1 1 1 1
40 1 3 2 1 1 6 6 4 4 1 2 0 2 1 1
45 1 1 1 2 1 3 4 3 3 1 2 0 1 1 1
41 2 3 2 1 1 3 4 3 3 2 1 2 3 1 4
34 2 2 1 2 1 4 7 2 3 1 2 0 1 1 1
49 1 3 2 2 1 7 5 3 4 2 2 0 2 1 1
30 1 1 1 1 2 3 3 3 3 1 1 1 1 2 1
33 2 2 1 2 1 6 7 4 4 1 2 0 1 1 1
46 1 1 1 1 1 3 4 3 3 1 2 0 1 1 1
49 1 4 2 1 2 4 4 4 3 3 1 2 2 3 1
38 2 2 1 1 1 7 3 4 4 1 2 0 1 1 1
41 1 1 2 2 1 6 7 6 4 2 1 3 2 2 1
37 2 3 2 1 1 7 7 6 5 2 1 1 3 2 2
44 1 1 1 1 1 5 3 3 3 2 2 1 1 1 1
47 2 1 2 1 1 7 6 5 4 3 2 2 2 2 1
30 1 1 1 1 2 4 4 4 3 1 2 0 1 1 1
37 2 3 1 1 1 2 3 2 2 1 2 0 2 1 1
34 1 1 1 1 2 3 3 3 3 1 1 1 1 3 1
MASTER    CHART - DM
Age Sex Religion Family Residence Marital st Education Occupation Income SES Duration Complications Hosp.stay Adherence BDI HAM-A
46 1 1 1 1 1 3 4 3 3 1 2 0 1 1 1
36 2 2 1 2 1 6 7 6 4 1 2 0 1 1 1
46 2 2 2 1 1 7 6 4 4 1 1 2 3 4 2
41 2 3 2 1 1 3 4 3 3 2 1 3 3 1 4
44 1 1 1 1 1 5 3 3 3 2 2 1 1 1 1
41 1 1 2 2 1 6 7 6 4 2 1 1 2 3 1
40 1 3 2 1 1 6 6 4 4 1 2 0 2 1 2
45 1 1 1 1 1 3 4 3 3 1 2 0 1 1 1
42 2 1 1 1 1 5 3 3 3 1 2 1 2 1 1
34 2 2 1 2 1 4 7 2 3 1 2 0 1 1 1
37 2 3 1 1 1 2 3 2 2 1 2 0 2 1 1
43 2 2 2 1 1 7 6 4 4 1 1 2 3 4 3
47 2 1 2 1 1 7 6 5 4 3 2 2 2 2 1
49 1 3 2 2 1 7 7 6 5 2 1 2 2 1 1
30 1 1 1 1 2 4 4 4 3 1 2 0 1 1 1
44 2 1 1 1 1 5 3 3 3 1 2 1 2 1 1
50 1 1 1 2 1 7 5 3 4 2 1 2 2 1 3
39 2 2 1 1 1 7 3 4 4 1 1 0 1 1 1
44 1 1 1 1 1 5 3 3 3 2 2 1 1 1 1
33 2 2 1 2 1 6 5 4 4 1 2 0 1 1 1
45 1 1 1 2 1 3 4 3 3 1 2 0 1 1 1
37 2 3 2 1 1 7 7 6 5 2 1 1 3 1 2
49 1 4 2 1 2 4 4 4 3 3 2 2 2 3 1
41 2 3 2 1 1 3 4 3 3 2 1 2 3 1 4
Age Sex Religion Family Residence Marital st Education Occupation Income SES Duration Complications Hosp.stay Adherence BDI HAM-A
38 2 3 1 1 1 5 7 5 4 1 2 1 1 1 1
39 1 3 2 1 1 6 6 4 4 1 2 0 2 1 1
38 2 3 1 1 1 5 4 5 4 1 2 1 1 1 1
37 2 3 2 1 1 7 7 6 5 2 2 1 3 1 2
47 2 1 2 1 1 7 6 5 4 3 2 2 2 2 1
34 2 2 1 2 1 4 7 2 3 1 2 0 1 1 1
48 1 1 1 2 1 7 5 3 4 2 1 2 2 1 3
41 1 1 2 2 1 6 7 6 4 2 1 1 2 1 1
45 1 1 1 2 1 3 4 3 3 1 2 0 1 1 1
40 2 2 1 1 1 7 3 4 4 1 2 0 1 1 1
30 1 1 1 1 2 4 4 4 3 1 2 0 1 1 1
37 2 3 1 1 1 2 3 2 2 1 2 0 2 1 1
48 1 4 2 1 2 4 4 4 3 3 1 2 2 3 1
46 1 3 2 2 1 7 5 3 4 2 1 0 2 1 1
31 1 1 1 1 2 3 3 3 3 1 2 1 1 1 1
Age Sex Religion Family Residence
Marital 
Status
Education Occupation Income SES Duration Complications
Hosp.
stay
Adherence BDI HAM-A
46 1 1 1 1 1 4 4 3 3 2 2 0 2 1 1
38 2 1 1 1 1 6 5 5 4 1 2 1 1 1 1
49 1 2 2 2 1 7 6 5 4 3 1 1 3 1 2
42 2 3 2 2 1 7 7 6 5 2 2 0 3 3 1
31 1 1 1 1 2 3 4 3 3 1 2 0 1 1 1
39 2 3 1 1 1 6 7 6 4 1 2 0 2 1 1
42 1 1 2 2 1 6 5 4 4 2 2 0 1 1 1
47 1 3 2 1 1 6 5 3 3 1 1 0 2 1 1
49 2 1 1 2 1 4 4 4 3 3 2 1 1 1 1
36 2 1 1 1 1 7 6 5 4 1 2 0 2 1 1
38 1 1 1 1 1 2 3 3 2 1 2 0 1 1 1
43 1 3 2 2 1 5 5 4 4 2 1 3 2 1 3
44 2 1 1 1 1 4 4 4 3 1 2 0 1 1 1
41 2 2 1 1 1 7 4 3 3 2 1 1 2 1 1
39 1 1 1 1 1 4 6 4 4 1 2 0 1 1 1
48 1 3 2 1 1 3 3 3 2 3 1 2 2 1 1
43 1 1 1 1 1 6 5 4 4 1 2 0 1 1 1
38 2 2 1 2 2 6 7 4 4 2 2 0 1 1 1
34 2 3 1 1 1 7 7 6 5 1 2 0 1 1 1
39 2 1 2 1 1 4 6 4 4 1 2 0 2 1 1
 MASTER  CHART - SHT
Age Sex Religion Family Residence
Marital 
Status
Education Occupation Income SES Duration Complications
Hosp.
stay
Adherence BDI HAM-A
39 2 3 1 1 1 6 7 6 4 1 2 0 2 1 1
48 1 3 2 1 1 6 5 3 3 1 1 0 2 1 1
42 2 3 2 2 1 7 7 6 5 2 2 0 3 2 1
38 1 1 1 1 1 2 3 3 2 1 2 0 1 1 1
39 1 1 1 1 1 4 6 4 4 1 2 0 1 1 1
42 1 1 2 2 1 6 5 4 4 2 2 0 1 1 1
46 2 1 2 1 1 4 6 4 4 1 2 0 2 1 1
49 1 2 2 2 1 7 6 5 4 3 1 2 3 1 2
43 1 3 2 1 1 3 3 3 2 3 1 2 2 1 1
39 2 3 1 1 1 7 7 6 5 1 2 0 1 1 1
41 2 1 1 1 1 7 6 5 4 1 2 0 2 1 1
49 2 1 1 1 1 4 4 4 3 1 2 0 1 1 1
50 2 3 2 2 1 7 7 6 5 2 2 0 2 3 1
44 2 1 2 1 1 4 6 4 4 1 2 0 2 1 1
36 2 1 1 1 1 7 6 5 4 1 2 0 2 1 1
38 2 1 1 1 1 6 5 5 4 1 1 1 2 1 3
49 2 1 1 2 1 4 4 4 3 3 2 1 1 1 1
43 1 1 1 1 1 6 5 4 4 1 2 0 1 1 1
46 1 1 1 1 1 4 4 3 3 2 2 0 2 1 1
41 2 2 1 1 1 7 4 3 3 2 1 1 2 1 1
39 1 1 1 1 1 4 6 4 4 1 2 0 1 1 1
38 1 1 1 1 1 2 3 3 2 1 2 0 1 1 1
Age Sex Religion Family Residence
Marital 
Status
Education Occupation Income SES Duration Complications
Hosp.
stay
Adherence BDI HAM-A
42 1 1 2 2 1 6 5 4 4 2 2 0 1 1 1
46 1 3 2 1 1 6 5 3 3 1 1 0 2 1 1
39 2 3 1 1 1 6 7 6 4 1 2 0 2 1 1
43 1 3 2 2 1 5 5 4 4 2 1 1 2 1 1
38 2 1 1 1 1 6 5 5 4 1 2 1 1 1 1
33 1 1 1 1 2 3 4 3 3 1 2 0 1 1 1
38 2 2 1 2 2 6 7 4 4 2 2 0 1 1 1
44 1 3 2 1 1 3 3 3 2 3 1 2 2 1 1
47 1 2 2 2 1 7 6 5 4 3 1 1 3 1 3
40 2 2 1 2 2 6 7 4 4 2 2 0 1 1 1
45 1 3 2 2 1 5 5 4 4 2 1 1 2 1 2
41 2 2 1 1 1 7 4 3 3 2 1 1 2 1 1
49 2 1 1 2 1 4 4 4 3 3 2 1 1 1 1
44 2 1 1 1 1 4 4 4 3 1 1 1 2 4 1
32 1 1 1 1 2 3 4 3 3 1 2 0 1 1 1
43 1 1 1 1 1 6 5 4 4 1 2 0 1 1 1
46 1 1 1 1 1 4 4 3 3 2 1 1 2 1 3
34 2 3 1 1 1 7 7 6 5 1 2 0 1 1 1
Age Sex Religion Family Residence Marital Status Education Occupation Income SES Duration Complications Hosp.stay Adherence BDI HAM-A
31 2 1 1 2 2 2 3 2 2 1 1 1 2 1 2
39 1 1 1 1 1 6 5 4 4 2 2 0 1 1 1
42 1 2 2 1 1 4 7 2 3 1 1 2 3 3 1
47 1 3 2 1 1 7 7 5 4 2 1 3 2 2 1
49 1 2 1 1 1 7 6 5 4 2 2 1 1 1 1
36 2 4 2 1 2 6 6 4 4 1 2 0 2 1 1
38 1 1 2 2 1 4 6 5 4 1 2 0 1 1 1
43 1 1 1 1 1 7 3 4 4 2 1 1 2 1 1
44 2 3 2 2 1 6 5 5 4 1 2 0 1 1 1
32 2 1 1 2 2 5 3 3 3 1 2 0 2 1 1
35 2 3 1 1 1 5 7 3 4 1 1 2 3 1 3
41 1 2 1 2 1 7 7 6 4 2 1 1 2 2 1
38 1 2 2 1 1 6 7 5 4 1 2 0 2 1 1
37 2 3 2 2 1 7 7 6 5 1 2 1 3 1 1
47 1 1 1 2 1 4 4 4 3 3 1 3 3 3 1
34 2 2 1 1 1 2 3 3 2 1 2 0 2 1 1
48 2 3 1 1 1 4 4 5 3 2 1 1 2 4 2
41 1 1 2 2 1 5 3 3 3 1 2 0 1 1 1
45 2 4 2 1 1 3 4 3 3 2 1 2 2 1 3
40 1 1 1 1 1 5 4 5 4 1 2 1 1 1 1
31 2 1 1 2 2 2 3 2 2 1 1 1 2 1 2
MASTER  CHART - COPD
Age Sex Religion Family Residence Marital Status Education Occupation Income SES Duration Complications Hosp.stay Adherence BDI HAM-A
36 2 4 2 1 2 6 6 4 4 1 2 0 2 1 1
47 2 1 1 2 2 5 3 3 3 1 2 0 2 1 1
47 1 3 2 1 1 7 7 5 4 2 1 3 2 3 1
39 1 1 1 1 1 6 5 4 4 2 2 0 1 1 1
47 1 1 1 2 1 4 4 4 3 3 1 3 3 4 1
49 1 2 1 1 1 7 6 5 4 2 2 1 1 1 1
42 1 2 2 1 1 4 7 2 3 1 1 2 3 3 1
38 1 2 1 2 1 7 7 6 4 2 1 1 2 2 1
45 2 4 2 1 1 3 4 3 3 2 1 2 2 1 3
49 1 2 2 1 1 4 7 2 3 1 1 2 3 3 1
39 1 2 2 1 1 6 7 5 4 1 2 0 2 1 1
35 2 3 1 1 1 5 7 3 4 1 1 3 3 1 3
41 1 1 2 2 1 5 3 3 3 1 2 0 3 1 1
33 2 1 1 2 2 2 3 2 2 1 1 1 2 1 2
40 1 1 1 1 1 5 4 5 4 1 2 1 1 1 1
43 1 1 1 1 1 7 3 4 4 2 1 1 2 1 1
37 2 3 2 2 1 7 7 6 5 1 2 1 3 1 1
41 1 1 1 1 1 6 5 4 4 2 2 0 1 1 1
47 1 1 1 2 1 4 4 4 3 3 1 2 3 3 1
48 2 3 1 1 1 4 4 5 3 2 1 1 2 4 2
34 2 2 1 1 1 2 3 3 2 1 2 0 1 1 1
39 2 3 2 2 1 7 7 6 5 1 2 1 3 1 1
43 1 2 1 2 1 7 7 6 4 2 1 1 2 2 1
Age Sex Religion Family Residence Marital Status Education Occupation Income SES Duration Complications Hosp.stay Adherence BDI HAM-A
45 2 4 2 1 1 3 4 3 3 2 1 2 2 1 4
43 1 1 2 2 1 5 3 3 3 1 2 0 1 1 1
43 2 4 2 1 1 3 4 3 3 2 1 2 2 1 3
47 1 2 2 1 1 4 7 2 3 1 1 2 3 3 1
46 1 3 2 1 1 7 7 5 4 2 1 3 2 3 1
40 1 1 1 1 1 5 4 5 4 1 2 1 1 1 1
37 2 2 1 1 1 2 3 3 2 1 2 0 1 1 1
45 2 4 2 1 1 3 4 3 3 2 1 2 2 1 3
43 1 1 1 1 1 7 3 4 4 2 1 1 2 1 1
32 2 1 1 2 2 5 3 3 3 1 2 0 2 1 1
42 1 2 2 1 1 6 7 5 4 1 2 0 2 1 1
45 1 2 2 1 1 4 7 2 3 1 1 2 3 3 1
49 1 2 1 1 1 7 6 5 4 2 2 1 1 1 1
38 2 4 2 1 2 6 6 4 4 1 2 0 2 1 1
48 2 3 1 1 1 4 4 5 3 2 1 1 2 3 2
35 2 3 1 1 1 5 7 3 4 1 1 2 3 1 3
